
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Dual ETA‐ETB receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="37B2C1FB7FFF828306C1FB001D59796B.m_1" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11981691/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Fundamental &amp; Clinical Pharmacology">
<meta name="citation_title" content="Dual ETA‐ETB receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction">
<meta name="citation_author" content="Francesca Lockwood">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author_institution" content="Institute for Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway">
<meta name="citation_author" content="Marianne Lachaux">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Najah Harouki">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Matthieu Soulié">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Lionel Nicol">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Sylvanie Renet">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Anaïs Dumesnil">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Magali Vercauteren">
<meta name="citation_author_institution" content="Idorsia Pharmaceuticals Ltd. Allschwil, Switzerland">
<meta name="citation_author" content="Jeremy Bellien">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Marc Iglarz">
<meta name="citation_author_institution" content="Idorsia Pharmaceuticals Ltd. Allschwil, Switzerland">
<meta name="citation_author" content="Vincent Richard">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_author" content="Paul Mulder">
<meta name="citation_author_institution" content="Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France">
<meta name="citation_publication_date" content="2025 Apr 9">
<meta name="citation_volume" content="39">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="e70006">
<meta name="citation_doi" content="10.1111/fcp.70006">
<meta name="citation_pmid" content="40203840">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11981691/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11981691/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11981691/pdf/FCP-39-0.pdf">
<meta name="description" content="Metabolic syndrome (MetS) is a multifaceted disease associated with heart failure (HF), which affects the vascular system. The endothelin (ET) system is a key player in MetS and HF; therefore, targets for ET receptors are of therapeutic interest. ...">
<meta name="og:title" content="Dual ETA‐ETB receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Metabolic syndrome (MetS) is a multifaceted disease associated with heart failure (HF), which affects the vascular system. The endothelin (ET) system is a key player in MetS and HF; therefore, targets for ET receptors are of therapeutic interest. ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11981691/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11981691">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1111/fcp.70006"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/FCP-39-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11981691%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11981691/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11981691/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11981691/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1111/fcp.70006" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Fundam Clin Pharmacol</button></div>. 2025 Apr 9;39(3):e70006. doi: <a href="https://doi.org/10.1111/fcp.70006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1111/fcp.70006</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Fundam%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fundam%20Clin%20Pharmacol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Fundam%20Clin%20Pharmacol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Fundam%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Dual ET<sub>A</sub>‐ET<sub>B</sub> receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lockwood%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Francesca Lockwood</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Francesca Lockwood</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Institute for Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lockwood%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesca Lockwood</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachaux%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Marianne Lachaux</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Marianne Lachaux</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lachaux%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marianne Lachaux</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harouki%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Najah Harouki</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Najah Harouki</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harouki%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Najah Harouki</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Souli%C3%A9%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Matthieu Soulié</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Matthieu Soulié</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Souli%C3%A9%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Matthieu Soulié</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nicol%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Lionel Nicol</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Lionel Nicol</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nicol%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lionel Nicol</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Renet%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Sylvanie Renet</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Sylvanie Renet</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Renet%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sylvanie Renet</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dumesnil%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Anaïs Dumesnil</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Anaïs Dumesnil</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dumesnil%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anaïs Dumesnil</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vercauteren%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Magali Vercauteren</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Magali Vercauteren</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Idorsia Pharmaceuticals Ltd. Allschwil, Switzerland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vercauteren%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Magali Vercauteren</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bellien%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Jeremy Bellien</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Jeremy Bellien</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bellien%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jeremy Bellien</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Iglarz%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Marc Iglarz</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Marc Iglarz</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Idorsia Pharmaceuticals Ltd. Allschwil, Switzerland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Iglarz%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marc Iglarz</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Richard%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Vincent Richard</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Vincent Richard</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Richard%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Vincent Richard</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mulder%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Paul Mulder</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Paul Mulder</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mulder%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Paul Mulder</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="fcp70006-aff-0001">
<sup>
<sup>1</sup>
</sup>Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France</div>
<div id="fcp70006-aff-0002">
<sup>
<sup>2</sup>
</sup>Institute for Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway</div>
<div id="fcp70006-aff-0003">
<sup>
<sup>3</sup>
</sup>Idorsia Pharmaceuticals Ltd. Allschwil, Switzerland</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence</strong>
, 
Paul Mulder, Univ Rouen Normandie, INSERM U1096, EnVI, 22 Bd Gambetta, Rouen F‐76000, France. 
Email: <span>paul.mulder@univ-rouen.fr</span>

</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Feb 19; Received 2024 Jul 24; Accepted 2025 Mar 5; Issue date 2025 Jun.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Fundamental &amp; Clinical Pharmacology</em> published by John Wiley &amp; Sons Ltd on behalf of Société Française de Pharmacologie et de Thérapeutique.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11981691  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40203840/" class="usa-link">40203840</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="fcp70006-sec-0001"><h3 class="pmc_sec_title">Background</h3>
<p>Metabolic syndrome (MetS) is a multifaceted disease associated with heart failure (HF), which affects the vascular system. The endothelin (ET) system is a key player in MetS and HF; therefore, targets for ET receptors are of therapeutic interest.</p></section><section id="fcp70006-sec-0002"><h3 class="pmc_sec_title">Objectives</h3>
<p>This study sought to evaluate the effects of macitentan, a dual endothelin receptor antagonist (ERA), in a rat model of MetS‐induced heart failure with preserved ejection fraction (HFpEF).</p></section><section id="fcp70006-sec-0003"><h3 class="pmc_sec_title">Methods</h3>
<p>We assessed in 12‐week‐old Zucker <em>fa/fa</em> rats the effects of macitentan (10 mg/kg/day as a food additive for short‐term/7‐ or long‐term/90‐day treatment) on right ventricular (RV) and left ventricular (LV) function/remodelling (MRI), RV and LV haemodynamics (catheterization) and RV and LV coronary function (myograph).</p></section><section id="fcp70006-sec-0004"><h3 class="pmc_sec_title">Results</h3>
<p>After 7‐ and 90‐days, untreated Zucker <em>fa/fa</em> rats presented isolated LV diastolic dysfunction (illustrated by elevated LV end‐diastolic pressure [EDP] and LV end‐diastolic pressure‐volume relationship [EDPVR] without changes in LV EDPVR). This was associated with increased collagen deposition and impaired endothelium‐dependent coronary artery relaxation. Macitentan 7‐ and 90‐day treatment significantly decreased blood pressure and prevented LV, RV and coronary dysfunctions and long‐term treatment reduced LV collagen density. Moreover, 7‐ and 90‐day macitentan treatment significantly reduced cardiac inflammation and reactive oxygen species (ROS) production.</p></section><section id="fcp70006-sec-0005"><h3 class="pmc_sec_title">Conclusions</h3>
<p>Dual ERA macitentan improved both LV and RV diastolic dysfunction. This was associated with improved coronary vasodilation, diminished cardiac oxidative stress and improved blood composition. These results suggest that antagonizing the ET system with macitentan is a promising approach to treat HFpEF and its complications.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> cardiac remodelling, endothelin, heart failure, metabolic syndrome</p></section></section><hr class="headless">
<h3>Abbreviations</h3>
<dl class="def-list" id="fcp70006-dl-0001">
<dt id="fcp70006-li-0001">CO</dt>
<dd id="fcp70006-li-0002"><p>cardiac output</p></dd>
<dt id="fcp70006-li-0003">CVD</dt>
<dd id="fcp70006-li-0004"><p>cardiovascular disease</p></dd>
<dt id="fcp70006-li-0005">DM</dt>
<dd id="fcp70006-li-0006"><p>diabetes mellitus</p></dd>
<dt id="fcp70006-li-0007">EDP</dt>
<dd id="fcp70006-li-0008"><p>end‐diastolic pressure</p></dd>
<dt id="fcp70006-li-0009">EDPVR</dt>
<dd id="fcp70006-li-0010"><p>end‐diastolic pressure‐volume relationship</p></dd>
<dt id="fcp70006-li-0011">EDV</dt>
<dd id="fcp70006-li-0012"><p>end‐diastolic volume</p></dd>
<dt id="fcp70006-li-0013">ERA</dt>
<dd id="fcp70006-li-0014"><p>endothelin receptor antagonist</p></dd>
<dt id="fcp70006-li-0015">ESP</dt>
<dd id="fcp70006-li-0016"><p>end‐systolic pressure</p></dd>
<dt id="fcp70006-li-0017">ESPVR</dt>
<dd id="fcp70006-li-0018"><p>end‐systolic pressure‐volume relationship</p></dd>
<dt id="fcp70006-li-0019">ESV</dt>
<dd id="fcp70006-li-0020"><p>end‐systolic volume</p></dd>
<dt id="fcp70006-li-0021">ET‐1</dt>
<dd id="fcp70006-li-0022"><p>endothelin‐1</p></dd>
<dt id="fcp70006-li-0023">ET<sub>A</sub>
</dt>
<dd id="fcp70006-li-0024"><p>endothelin type A receptor</p></dd>
<dt id="fcp70006-li-0025">ET<sub>B</sub>
</dt>
<dd id="fcp70006-li-0026"><p>endothelin type B receptor</p></dd>
<dt id="fcp70006-li-0027">HF</dt>
<dd id="fcp70006-li-0028"><p>heart failure</p></dd>
<dt id="fcp70006-li-0029">HFpEF</dt>
<dd id="fcp70006-li-0031"><p>heart failure with preserved ejection fraction</p></dd>
<dt id="fcp70006-li-0032">HFrEF</dt>
<dd id="fcp70006-li-0033"><p>heart failure with reduced ejection fraction</p></dd>
<dt id="fcp70006-li-0034">LV</dt>
<dd id="fcp70006-li-0035"><p>left ventricle</p></dd>
<dt id="fcp70006-li-0036">MetS</dt>
<dd id="fcp70006-li-0037"><p>metabolic syndrome</p></dd>
<dt id="fcp70006-li-0038">NT‐ProBNP</dt>
<dd id="fcp70006-li-0039"><p>N‐terminal prohormone of brain natriuretic peptide</p></dd>
<dt id="fcp70006-li-0040">PAH</dt>
<dd id="fcp70006-li-0041"><p>pulmonary arterial hypertension</p></dd>
<dt id="fcp70006-li-0042">PH</dt>
<dd id="fcp70006-li-0043"><p>pulmonary hypertension</p></dd>
<dt id="fcp70006-li-0044">ROS</dt>
<dd id="fcp70006-li-0045"><p>reactive oxygen species</p></dd>
<dt id="fcp70006-li-0046">RV</dt>
<dd id="fcp70006-li-0047"><p>right ventricle</p></dd>
<dt id="fcp70006-li-0048">SGLT2i</dt>
<dd id="fcp70006-li-0049"><p>sodium‐glucose co‐transporter‐type‐2 inhibitors</p></dd>
<dt id="fcp70006-li-0050">T2DM</dt>
<dd id="fcp70006-li-0051"><p>type II diabetes mellitus</p></dd>
<dt id="fcp70006-li-0052">VSMC</dt>
<dd id="fcp70006-li-0053"><p>vascular smooth muscle cells</p></dd>
</dl>
<section id="fcp70006-sec-0006"><h2 class="pmc_sec_title">1. INTRODUCTION</h2>
<p>Metabolic syndrome (MetS), also known as syndrome X, is a leading global challenge affecting 23.9% of men and 24.6% of women in the western world [<a href="#fcp70006-bib-0001" class="usa-link" aria-describedby="fcp70006-bib-0001">1</a>]. It is a multifaceted disease requiring clinical and qualitative assessment of the patients, and it serves as an umbrella term for the association with other diseases including obesity, diabetes mellitus (DM), heart failure (HF) and pulmonary hypertension (PH) [<a href="#fcp70006-bib-0002" class="usa-link" aria-describedby="fcp70006-bib-0002">2</a>, <a href="#fcp70006-bib-0003" class="usa-link" aria-describedby="fcp70006-bib-0003">3</a>, <a href="#fcp70006-bib-0004" class="usa-link" aria-describedby="fcp70006-bib-0004">4</a>]. Untreated patients risk developing HF, which is a leading cause of mortality worldwide; therefore, it is beneficial to explore effective therapies for these intertwined diseases [<a href="#fcp70006-bib-0004" class="usa-link" aria-describedby="fcp70006-bib-0004">4</a>]. HF is divided into three categories; heart failure with reduced ejection fraction (HFrEF), HF with mild reduced ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF) [<a href="#fcp70006-bib-0005" class="usa-link" aria-describedby="fcp70006-bib-0005">5</a>, <a href="#fcp70006-bib-0006" class="usa-link" aria-describedby="fcp70006-bib-0006">6</a>]. HFpEF is more prevalent than HFrEF and harder to treat, which enforces the need to investigate other mechanisms for therapeutic targets [<a href="#fcp70006-bib-0005" class="usa-link" aria-describedby="fcp70006-bib-0005">5</a>].</p>
<p>HFpEF is a serious global disease, which affects multiple organ systems and is heavily associated with obesity and metabolic dysfunctions; hence, it has a strong link to MetS [<a href="#fcp70006-bib-0004" class="usa-link" aria-describedby="fcp70006-bib-0004">4</a>, <a href="#fcp70006-bib-0007" class="usa-link" aria-describedby="fcp70006-bib-0007">7</a>, <a href="#fcp70006-bib-0008" class="usa-link" aria-describedby="fcp70006-bib-0008">8</a>]. HFpEF is characterized by a decrease in left ventricular (LV) relaxation with a preserved LV ejection fraction (EF) of 50% or more, alongside LV remodelling such as collagen deposition and diastolic dysfunction [<a href="#fcp70006-bib-0005" class="usa-link" aria-describedby="fcp70006-bib-0005">5</a>, <a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>]. HFpEF also affects the vasculature which may be part of the explanation for the involvement of the renal and pulmonary systems [<a href="#fcp70006-bib-0008" class="usa-link" aria-describedby="fcp70006-bib-0008">8</a>]. Endothelin‐1 (ET‐1), which causes vasoconstriction, is increased in patients with HF, including HFpEF. ET‐1 may also contribute to cardiac dysfunction, via vasoconstriction and the promotion of endothelial dysfunction [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>]. Furthermore, PH and in particular pulmonary arterial hypertension (PAH) associated with right ventricular (RV) dysfunction has been linked to ET‐1 dysfunction [<a href="#fcp70006-bib-0010" class="usa-link" aria-describedby="fcp70006-bib-0010">10</a>]. A dual endothelin type A and B (ET<sub>A</sub>, ET<sub>B</sub>) receptor antagonist macitentan is approved for the treatment for PAH (WHO Group I) and has been shown to be beneficial to treat PH [<a href="#fcp70006-bib-0010" class="usa-link" aria-describedby="fcp70006-bib-0010">10</a>, <a href="#fcp70006-bib-0011" class="usa-link" aria-describedby="fcp70006-bib-0011">11</a>]. Macitentan prevents the binding of ET‐1 to the ET<sub>A</sub> and ET<sub>B</sub> receptors on the vascular smooth muscle cells, thereby preventing ET‐1‐mediated vasoconstriction, leading to decreased pulmonary blood pressure [<a href="#fcp70006-bib-0010" class="usa-link" aria-describedby="fcp70006-bib-0010">10</a>]. Furthermore, due to the link between hypertension and type II diabetes mellitus (T2DM), targeting ET‐1 appears to be a suitable option for the treatment of T2DM, shown by the use of macitentan and other endothelin receptor antagonists (ERA) in several studies [<a href="#fcp70006-bib-0012" class="usa-link" aria-describedby="fcp70006-bib-0012">12</a>, <a href="#fcp70006-bib-0013" class="usa-link" aria-describedby="fcp70006-bib-0013">13</a>, <a href="#fcp70006-bib-0014" class="usa-link" aria-describedby="fcp70006-bib-0014">14</a>, <a href="#fcp70006-bib-0015" class="usa-link" aria-describedby="fcp70006-bib-0015">15</a>]. According to the American Heart Association, DM patients age 65 years and above have 68% mortality rate from heart disease [<a href="#fcp70006-bib-0016" class="usa-link" aria-describedby="fcp70006-bib-0016">16</a>]. This highlights the need for new therapies targeting comorbidities related to cardiovascular disease (CVD).</p>
<p>The current treatment for HFpEF is diuretics, sodium‐glucose co‐transporter type‐2 inhibitors (SGLT2i) and treatment of the aetiology and comorbidities [<a href="#fcp70006-bib-0017" class="usa-link" aria-describedby="fcp70006-bib-0017">17</a>, <a href="#fcp70006-bib-0018" class="usa-link" aria-describedby="fcp70006-bib-0018">18</a>]. However, these classical treatments, which are effective in the treatment of HFrEF, show less efficacy in HFpEF patients, which may be due to the comorbidities associated with the disease [<a href="#fcp70006-bib-0019" class="usa-link" aria-describedby="fcp70006-bib-0019">19</a>, <a href="#fcp70006-bib-0020" class="usa-link" aria-describedby="fcp70006-bib-0020">20</a>, <a href="#fcp70006-bib-0021" class="usa-link" aria-describedby="fcp70006-bib-0021">21</a>, <a href="#fcp70006-bib-0022" class="usa-link" aria-describedby="fcp70006-bib-0022">22</a>]. Among several targets involved in PH associated with HFpEF, ET‐1 is particularly interesting as it is involved in precapillary PH and activated in HFrEF and HFpEF associated or not with DM [<a href="#fcp70006-bib-0023" class="usa-link" aria-describedby="fcp70006-bib-0023">23</a>, <a href="#fcp70006-bib-0024" class="usa-link" aria-describedby="fcp70006-bib-0024">24</a>, <a href="#fcp70006-bib-0025" class="usa-link" aria-describedby="fcp70006-bib-0025">25</a>]. Furthermore ET‐1 promotes collagen deposition, leading to cardiac fibrosis, a major mechanism involved in diastolic dysfunction and HFpEF [<a href="#fcp70006-bib-0026" class="usa-link" aria-describedby="fcp70006-bib-0026">26</a>, <a href="#fcp70006-bib-0027" class="usa-link" aria-describedby="fcp70006-bib-0027">27</a>]. Since dual ERAs, such as macitentan, demonstrated the role of ET‐1 in the development of PH, RV dysfunction and DM, we hypothesized that a dual ERA might be beneficial in a model of HFpEF with PH and T2DM characteristics [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>, <a href="#fcp70006-bib-0011" class="usa-link" aria-describedby="fcp70006-bib-0011">11</a>, <a href="#fcp70006-bib-0028" class="usa-link" aria-describedby="fcp70006-bib-0028">28</a>]. Furthermore, as the incidence of MetS and HFpEF is increasing our aim was to investigate these two comorbidities in a rodent model [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>, <a href="#fcp70006-bib-0028" class="usa-link" aria-describedby="fcp70006-bib-0028">28</a>, <a href="#fcp70006-bib-0029" class="usa-link" aria-describedby="fcp70006-bib-0029">29</a>, <a href="#fcp70006-bib-0030" class="usa-link" aria-describedby="fcp70006-bib-0030">30</a>, <a href="#fcp70006-bib-0031" class="usa-link" aria-describedby="fcp70006-bib-0031">31</a>, <a href="#fcp70006-bib-0032" class="usa-link" aria-describedby="fcp70006-bib-0032">32</a>, <a href="#fcp70006-bib-0033" class="usa-link" aria-describedby="fcp70006-bib-0033">33</a>].</p>
<p>Thus, the aims of this study were to assess (1) whether a previously established model of MetS, Zucker <em>fa/fa</em> rats is associated with a development of HFpEF, RV and LV hypertrophy/dysfunction and PH characteristics; (2) whether the dual ERA macitentan improves RV, LV and systemic haemodynamics, RV and LV function and morphological alterations.</p></section><section id="fcp70006-sec-0007"><h2 class="pmc_sec_title">2. METHODS AND MATERIALS</h2>
<section id="fcp70006-sec-0008"><h3 class="pmc_sec_title">2.1. Animals and treatment</h3>
<p>All animal procedures performed conformed to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes and was approved by the local ethical comity CENOMEXA n°54 (authorization number: 05.231.01).</p>
<p>This study was performed in 12‐week‐old male Zucker lean fa/+ and obese Zucker <em>fa/fa</em> rats, which are a model of HFpEF (Charles River Laboratories, France). Animals were kept two per cage in standard laboratory conditions [<a href="#fcp70006-bib-0034" class="usa-link" aria-describedby="fcp70006-bib-0034">34</a>]. For methods of analysis, all operators were blinded during data analysis. Animals were monitored at least daily throughout the studies for any signs of discomfort according to the grimace scale. Discomfort according to the grimace scale that was moderate or more or could not be alleviated would have been a humane end‐point but fortunately no adverse effects or stress behaviours were observed from the animals.</p></section><section id="fcp70006-sec-0009"><h3 class="pmc_sec_title">2.2. Studies and objectives</h3>
<ul id="fcp70006-list-0001" class="list" style="list-style-type:none">
<li id="fcp70006-li-0054">
<span class="long-label">Study 1:</span><p>Short‐term macitentan treatment for 7 days to evaluate the acute effect of macitentan independent of cardiac remodelling which occurs over a longer period of time.</p>
</li>
<li id="fcp70006-li-0055">
<span class="long-label">Study 2:</span><p>To evaluate the effects of long‐term/chronic macitentan treatment for 90 days alongside cardiac remodelling.</p>
</li>
</ul>
<p>Both studies underwent the same analysis except for RV haemodynamics, which was only assessed in Study 2.</p>
<section class="bt xbox font-sm" id="fcp70006-blkfxd-0001"><p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f53e/11981691/d88c9d199626/FCP-39-0-g001.jpg" loading="lazy" id="jats-graphic-1" height="390" width="709" alt="2.2."></p></section><p>Experimental design schema</p></section><section id="fcp70006-sec-0010"><h3 class="pmc_sec_title">2.3. Study descriptions</h3>
<ul id="fcp70006-list-0002" class="list" style="list-style-type:none">
<li id="fcp70006-li-0056">
<span class="long-label">Study 1:</span><p>Zucker <em>fa/fa</em> rats were randomized by Latin square design randomization at the age of 12 weeks in two groups, either untreated (<em>n</em> = 14) or treated for 7 days with macitentan 10 mg.kg<sup>−1</sup>.day<sup>−1</sup> (<em>n</em> = 14) administered as food additive as previously described until the rats were 13 weeks old [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>, <a href="#fcp70006-bib-0035" class="usa-link" aria-describedby="fcp70006-bib-0035">35</a>]. Untreated Zucker lean fa/+ animals were used as healthy controls from 12 weeks old to 13 weeks old (<em>n</em> = 12).</p>
</li>
<li id="fcp70006-li-0057">
<span class="long-label">Study 2:</span><p>Zucker <em>fa/fa</em> rats were randomized by Latin square design randomization at the age of 12 weeks in two groups either untreated (<em>n</em> = 14) or treated for 90 days with macitentan 10 mg.kg<sup>−1</sup>.day<sup>−1</sup> (<em>n</em> = 14) administered as food additive as previously described until the rats were 24 weeks old [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>, <a href="#fcp70006-bib-0035" class="usa-link" aria-describedby="fcp70006-bib-0035">35</a>]. Untreated Zucker lean fa/+ animals were used as healthy controls (<em>n</em> = 12) from 12 weeks old to 24 weeks old.</p>
</li>
</ul></section><section id="fcp70006-sec-0011"><h3 class="pmc_sec_title">2.4. Methods of analysis</h3>
<section id="fcp70006-sec-0012"><h4 class="pmc_sec_title">2.4.1. Blood pressure and heart rate (HR) assessment</h4>
<p>Blood pressure and HR were measured in conscious rats by telemetry (<em>n</em> = 6 per group) (Dataquest ART system, Data Sciences Inc., St Paul, Minn, USA) as previously described [<a href="#fcp70006-bib-0036" class="usa-link" aria-describedby="fcp70006-bib-0036">36</a>].</p></section><section id="fcp70006-sec-0013"><h4 class="pmc_sec_title">2.4.2. ET<sub>A</sub>‐ET<sub>B</sub> receptor blockade</h4>
<p>To confirm ET receptor blockade, the blood pressure variation induced by ET‐1 (1 nmol.kg<sup>−</sup> IV bolus injection) were assessed after 7 and 90 days of macitentan administration in (<em>n</em> = 3) randomly selected animals from each group, as previously described [<a href="#fcp70006-bib-0037" class="usa-link" aria-describedby="fcp70006-bib-0037">37</a>].</p></section><section id="fcp70006-sec-0014"><h4 class="pmc_sec_title">2.4.3. RV and LV volumes</h4>
<p>MRI was performed using a 4.7‐T BIOSPEC (Bruker, Germany) as previously described [<a href="#fcp70006-bib-0038" class="usa-link" aria-describedby="fcp70006-bib-0038">38</a>]. After anaesthesia (sodium methohexital, 60 mg/kg IP), using the Intragate sequence (Bruker, France), 12 continuous ventricular short‐axis slices of 1.5 mm thickness with no inter‐slice gap were acquired to cover the entire range of both ventricles. Data analysis was performed with an operator‐interactive threshold technique by one trained observer using FARM‐CAAS 2.0 software (Pie Medical, Netherlands). RV (7‐day: lean <em>n</em> = 11, untreated <em>n</em> = 14 and treated <em>n</em> = 14. 90‐day: lean <em>n</em> = 8, untreated <em>n</em> = 10 and treated <em>n</em> = 10) and LV (7‐day: lean <em>n</em> = 9, untreated <em>n</em> = 11 and treated <em>n</em> = 13. 90‐day: lean <em>n</em> = 9, untreated <em>n</em> = 11 and treated <em>n</em> = 12) volumes were determined from end‐diastolic and end‐systolic images by multiplication of RV and LV compartment area and slice thickness (1.5 mm). Total volumes were calculated as the sum of all slice volumes. EF was calculated with the end‐diastolic volume (EDV) and end‐systolic volume (ESV) (EF = SV/EDV). Cardiac output (CO) was calculated as (EDV‐ESV) multiplied by HR.</p></section><section id="fcp70006-sec-0015"><h4 class="pmc_sec_title">2.4.4. LV tissue perfusion</h4>
<p>At the end of the 7‐day and 90‐day studies, myocardial tissue perfusion (7‐day: lean <em>n</em> = 10, untreated <em>n</em> = 6 and treated <em>n</em> = 6, 90‐day: lean <em>n</em> = 8, untreated <em>n</em> = 9 and treated <em>n</em> = 8) was evaluated using the same MRI equipment by Arterial Spin Labelling (ASL), in which, the blood in the arteries upstream from the imaging volume is magnetically labelled. This results in image intensity changes that will occur depending on the blood supply to the tissue in the imaged slice. Upon subtraction of an image acquired without spin labelling, the background signal from static spins is removed, and the image can be used to quantify perfusion. The difference of the inverse of the apparent T1 images then yields a measure of the regional cardiac blood flow (rCBF) according to rCBF = l (1/T1sel‐1/T1nonsel), where l is the blood‐tissue partition coefficient [<a href="#fcp70006-bib-0039" class="usa-link" aria-describedby="fcp70006-bib-0039">39</a>].</p></section><section id="fcp70006-sec-0016"><h4 class="pmc_sec_title">2.4.5. RV and LV haemodynamics</h4>
<p>At the end of the 7‐day (LV; lean <em>n</em> = 6, untreated <em>n</em> = 9 and treated <em>n</em> = 9) and 90‐day (LV; lean <em>n</em> = 6, untreated <em>n</em> = 9 and treated <em>n</em> = 9. RV; lean <em>n</em> = 9, untreated <em>n</em> = 9 and treated <em>n</em> = 7) studies, rats were anesthetized (sodium methohexital, 60 mg/kg, IP) and a Millar microtip manometer was introduced either into the RV (via the jugular vein) or the LV (via the carotid artery) for recording of RV and LV systolic (RVSP and LVSP), end‐diastolic pressures (RVEDP and LVEDP), the maximum rate of rise of RVSP and LVSP (LV dP/dt<sub>max</sub> and dP/dt<sub>max)</sub> and RV and LV relaxation constant Tau, as previously described [<a href="#fcp70006-bib-0040" class="usa-link" aria-describedby="fcp70006-bib-0040">40</a>]. Moreover, LV pressure‐volume loops were obtained at baseline and during loading by gently occluding the abdominal aorta with a cotton swab. Data were stored and analysed by using Millar conductance data acquisition and analysis software (IOX™, EMKA, France) and LV end‐systolic as well as end‐diastolic pressure‐volume relationship (EDPVR) were calculated.</p></section><section id="fcp70006-sec-0017"><h4 class="pmc_sec_title">2.4.6. LV histomorphology</h4>
<p>At the end of the treatment periods, the heart was dissected; the atria as well as the right and left ventricle were weighted separately (7‐day: lean <em>n</em> = 7, untreated <em>n</em> = 10 and treated <em>n</em> = 10, 90‐day: lean <em>n</em> = 11, untreated <em>n</em> = 10 and treated <em>n</em> = 9), and sections of the LV were either immersed in fixative solution or snap‐frozen in liquid nitrogen for subsequent assessment of LV collagen or LV immunohistochemistry as previously described [<a href="#fcp70006-bib-0041" class="usa-link" aria-describedby="fcp70006-bib-0041">41</a>]. Before harvesting, body weight was measured and after removal of the heart, lung weight was also measured (7‐day: lean <em>n</em> = 7, untreated <em>n</em> = 10 and treated <em>n</em> = 10, 90‐day: lean <em>n</em> = 11, untreated <em>n</em> = 10 and treated <em>n</em> = 9).</p>
<p>LV collagen density was determined on Sirius‐red stained slices in the 7‐ and 90‐day studies (7‐day: lean <em>n</em> = 10, untreated <em>n</em> = 6 and treated <em>n</em> = 6, 90‐day: lean <em>n</em> = 8, untreated <em>n</em> = 9 and treated <em>n</em> = 8). In brief, after fixation, sections were embedded in paraffin, and 5 μm thick slices were obtained and stained with Sirius Red for collagen determination by image analysis. Collagen density was expressed as the surface area occupied by collagen divided by the total surface area of the image.</p>
<p>LV capillary density and LV macrophage M1/2‐populations were obtained by immunohistology from frozen slices (7‐day: lean <em>n</em> = 10, untreated <em>n</em> = 6 and treated <em>n</em> = 6, 90‐day: lean <em>n</em> = 8, untreated <em>n</em> = 9 and treated <em>n</em> = 8), as previously described [<a href="#fcp70006-bib-0042" class="usa-link" aria-describedby="fcp70006-bib-0042">42</a>]. In brief, cryosections were stained using biotinylated mouse anti‐rat CD31 (BD Biosciences, 555 026, 1/100) and mouse anti‐human smooth muscle α actin (Sigma, F3777, 1/200), for the detection of blood vessels. Macrophages were visualized using biotinylated rat anti‐mouse F4/80 (Abcam, 192 834, 1/75) together with rabbit anti‐mouse CD206/MRC‐1, followed by Cy3‐conjugated donkey anti‐rabbit IgG. Biotinylated primary antibodies were revealed using SA‐Alexa 488 (FluoProbes, 1/400).</p></section><section id="fcp70006-sec-0018"><h4 class="pmc_sec_title">2.4.7. RV and LV oxidative stress</h4>
<p>RV and LV reactive oxygen species (ROS) production were determined after the 7‐ and 90‐day studies (7‐day: lean <em>n</em> = 10, untreated <em>n</em> = 6 and treated <em>n</em> = 6, 90‐day: lean <em>n</em> = 8, untreated <em>n</em> = 9 and treated <em>n</em> = 8) by electron paramagnetic resonance spectroscopy, as previously described [<a href="#fcp70006-bib-0043" class="usa-link" aria-describedby="fcp70006-bib-0043">43</a>]. Snap‐frozen biopsies of LV or RV tissues collected from the ventricle were homogenized and incubated at 37°C for 60 min in 50 mmol/L phosphate buffer containing 25 μmol/L deferoxamine, 5 μmol/L diethyldithiocarbamate, and 500 μmol/L 1‐hydroxy‐3‐methocarbonyl‐2,2,5,5‐tetramethyl pyrrolidine hydrochloride (CMH, Noxygen, Hamburg, Germany). The oxidation of CMH into the paramagnetic nitroxide CM<sup>•</sup>, driven mainly by superoxide and peroxynitrite reactions, was measured by electron paramagnetic resonance exactly 60 min after the beginning of incubation. Tissues were introduced into an insulin syringe and frozen in liquid nitrogen. Spectra were recorded at 77 K in a liquid nitrogen cooled dewar using an MS200 spectrometer (Magnettech, Berlin, Germany) with the following acquisition parameters: microwave power: 20 mW; microwave frequency: 9.54 GHz; modulation amplitude: 5 G; modulation frequency: 100 kHz; gain: 2 × 10 [<a href="#fcp70006-bib-0002" class="usa-link" aria-describedby="fcp70006-bib-0002">2</a>]; sweep time 120 s and number of scans 2. Intensity of the spectra was measured from the height of the central line and expressed in arbitrary units (AU) per mg of protein.</p></section><section id="fcp70006-sec-0019"><h4 class="pmc_sec_title">2.4.8. Right and septal coronary vascular function</h4>
<p>Coronary endothelium‐dependent relaxation (7‐day: RV; lean <em>n</em> = 6, untreated <em>n</em> = 4 and treated <em>n</em> = 5 and LV; lean <em>n</em> = 4, untreated <em>n</em> = 6 and treated <em>n</em> = 8. 90‐day: RV; lean <em>n</em> = 4, untreated <em>n</em> = 6 and treated <em>n</em> = 8 and LV; lean <em>n</em> = 4, untreated <em>n</em> = 6 and treated <em>n</em> = 7) was assessed ex vivo by obtaining concentration–relaxing response curves to acetylcholine as described previously [<a href="#fcp70006-bib-0044" class="usa-link" aria-describedby="fcp70006-bib-0044">44</a>]. Briefly, the heart was removed and placed in cold, oxygenated Krebs buffer. Segments of septal coronary artery (1.5 mm long and ∼180 to 250 μm in diameter), or of right coronary artery (1.5 mm long and ∼120 to 175 μm in diameter) were carefully dissected and mounted in a small vessel myograph for isometric tension recording (Dual Wire Myograph System; Danish Myo Technology). Endothelium‐dependent relaxations to acetylcholine (10<sup>−9</sup> to 10<sup>–4.5</sup> M) were assessed after vessel contraction with 10<sup>−5</sup> M serotonin.</p></section><section id="fcp70006-sec-0020"><h4 class="pmc_sec_title">2.4.9. LV mRNA quantification</h4>
<p>RNA was extracted from LV (7‐day study; lean <em>n</em> = 5, untreated <em>n</em> = 7 and treated <em>n</em> = 8. 90‐day study: lean <em>n</em> = 4, untreated <em>n</em> = 6 and treated <em>n</em> = 6) with the TRIzol reagent (Gibco life science) according to the manufacturer's instructions. RNA quantity and purity were assessed with a NanoDrop 1000 Spectrophotometer (NanoDrop Technologies). Quantitative real‐time reverse transcription‐polymerase chain reaction (RT‐PCR) was performed with a light‐cycler (Roche, Basel, Switzerland) using SYBR green primers. The primers were obtained from Sigma‐Aldrich and the sequences are presented in the table below:</p>
<section class="tw xbox font-sm" id="jats-table-wrap-1"><div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Forward</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Reverse</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">GAPDH</td>
<td align="left" valign="top" rowspan="1" colspan="1">GGCTGCCTTCTCTTGTGACA</td>
<td align="left" valign="top" rowspan="1" colspan="1">ACCAGCTTCCATTCTAGC</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Tubulin</td>
<td align="left" valign="top" rowspan="1" colspan="1">GTGTCCACCATCATGTCAGC</td>
<td align="left" valign="top" rowspan="1" colspan="1">GAGGAAGTGTAGTCGAGGGG</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">EEF2</td>
<td align="left" valign="top" rowspan="1" colspan="1">AATCTGACCCTGTCGTGTCC</td>
<td align="left" valign="top" rowspan="1" colspan="1">GTTGTGCTTGTTTGGGACT</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">ANP</td>
<td align="left" valign="top" rowspan="1" colspan="1">AGCCGAGACAGCAAACATCA</td>
<td align="left" valign="top" rowspan="1" colspan="1">TGGACACCGCACTGTATACG</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">BNP</td>
<td align="left" valign="top" rowspan="1" colspan="1">AGCTCTCAAAGGACCAAGGC</td>
<td align="left" valign="top" rowspan="1" colspan="1">TCCGGTCTATCTTCTGCCCA</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">SOD2</td>
<td align="left" valign="top" rowspan="1" colspan="1">GACATTGTGCCTCTGGGTTT</td>
<td align="left" valign="top" rowspan="1" colspan="1">GCCCTGCATACTTTGTCCAT</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">SOD1</td>
<td align="left" valign="top" rowspan="1" colspan="1">GCTTCTGTCGTCTCCTTGCT</td>
<td align="left" valign="top" rowspan="1" colspan="1">CTCGAAGTGAATGACGCCCT</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">NOX 4</td>
<td align="left" valign="top" rowspan="1" colspan="1">TTGGTGAACGCCCTGAACTT</td>
<td align="left" valign="top" rowspan="1" colspan="1">TACCACCACCATGCAGACAC</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Xanthine oxidase</td>
<td align="left" valign="top" rowspan="1" colspan="1">TGCCAGACCATACTGAAAAGG</td>
<td align="left" valign="top" rowspan="1" colspan="1">AAGCCACCCCATAACTGAAAT</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jats-table-wrap-1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>Results were normalized to the average expression of three housekeeping genes: GAPDH, tubulin and EEF2.</p></section><section id="fcp70006-sec-0021"><h4 class="pmc_sec_title">2.4.10. Plasma and urinary biology</h4>
<p>During the 90‐day study using metabolic cages, urine was collected overnight on the final night (lean <em>n</em> = 8, untreated <em>n</em> = 7 and treatment <em>n</em> = 7) and at the end of the 7‐ and 90‐day studies, plasma samples (7‐day: lean <em>n</em> = 7, untreated <em>n</em> = 4 and treated <em>n</em> = 4. 90‐day: lean <em>n</em> = 6, untreated <em>n</em> = 12 and treated <em>n</em> = 13) were obtained for subsequent determination of triglycerides, HDL‐C/LDL‐C, albumin and creatinine, which were measured using a Catalysts analyser (IDEXX France). Galectin‐3, ET‐1 and N‐terminal prohormone of brain natriuretic peptide (NT‐ProBNP) were determined using an ELISA kit (Abcam, Cambridge, UK), a chemiluminescent immunoassay (QuantiGlo; R&amp;D Systems GmbH, Wiesbaden‐Nordenstadt, Germany) and an MSD assay kit (Meso Scale Discovery, Rockville, MD), respectively.</p></section><section id="fcp70006-sec-0022"><h4 class="pmc_sec_title">2.4.11. Statistical analysis</h4>
<p>All results are given as mean ± SEM. RV and LV diastolic/systolic diameters and haemodynamic parameters were assessed as a primary end‐point, whereas all other parameters, that is, the molecular mechanisms, were assessed as secondary end‐points. Based upon historical data obtained with other drugs in Zucker <em>fa/fa</em> rats, we determined the sample sizes and made a simulation for each parameter obtained in untreated animals to demonstrate a statistical significance (<em>P</em> &lt; 0.05) with a minimal power of 80% [<a href="#fcp70006-bib-0040" class="usa-link" aria-describedby="fcp70006-bib-0040">40</a>, <a href="#fcp70006-bib-0045" class="usa-link" aria-describedby="fcp70006-bib-0045">45</a>]. The minimal expected difference between untreated and treated was fixed to 10%, with a coefficient of variation of 15% for echocardiographic and haemodynamic studies. For all significant differences concerning primary end‐points, a posteriori power higher than 80% was also checked.</p>
<p>In order to evaluate the effect of HFpEF, all measurements obtained in untreated Zucker <em>fa/fa</em> and lean rats were compared by Student's unpaired two‐tailed <em>t</em>‐test. To evaluate the effects of 7‐ or 90‐day macitentan treatment, all measurements obtained in 7‐ and 90‐day macitentan‐treated Zucker <em>fa/fa</em> rats were compared with time‐matched untreated Zucker <em>fa/fa</em> using Student's unpaired two‐tailed <em>t</em>‐test.</p>
<p>For vascular studies, differences between groups were analysed by two‐factor repeated ANOVA.</p>
<p>Before applying parametric tests such as Student's unpaired two‐tailed <em>t</em>‐test, the Gaussian distribution of data was assessed by Shapiro–Wilk normality test and Kolmogorov–Smirnov test and graphically by QQplot and normal probability plot.</p>
<p>There were no exclusions from experiments or analysis.</p></section></section></section><section id="fcp70006-sec-0023"><h2 class="pmc_sec_title">3. RESULTS</h2>
<p>The same parameters were measured in both studies except RV haemodynamics, and we wanted to compare 7‐day to 90‐day treatment effectiveness; therefore, to prevent repetition, the results are presented under the same sections and figures.</p>
<section id="fcp70006-sec-0024"><h3 class="pmc_sec_title">3.1. Systemic blood pressure</h3>
<p>Systolic and diastolic pressures and HR were recorded by telemetry in untreated or macitentan‐treated Zucker rats for the duration of both studies. At Day 0, blood pressure and HR were identical in both Zucker <em>fa/fa</em> groups. Macitentan administration reduced blood pressure reaching statistical significance at D<sub>90</sub>without modification of HR (Figure <a href="#fcp70006-fig-0001" class="usa-link">1</a> and Table <a href="#fcp70006-supitem-0001" class="usa-link">S1</a>).</p>
<figure class="fig xbox font-sm" id="fcp70006-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f53e/11981691/c313d128f4bc/FCP-39-0-g004.jpg" loading="lazy" id="jats-graphic-3" height="791" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70006-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>
<strong>Blood pressure and heart rate.</strong> Twenty‐four hour measurements of diastolic and systolic blood pressure (upper panel) as well as heart rate (lower panel) assessed by telemetry in conscious untreated Zucker <em>fa/fa</em> rats (open circles), and in Zucker <em>fa/fa</em> macitentan‐treated rats before (Day 0) and after 1, 7 and 90 days macitentan administration (black circles). Black bars indicate lights off. Each point is the mean of 6 animals.</p></figcaption></figure></section><section id="fcp70006-sec-0025"><h3 class="pmc_sec_title">3.2. RV function and haemodynamics</h3>
<p>Study 1: In 7‐day untreated Zucker <em>fa/fa</em> rats, RV function was preserved, shown by similar CO values compared to lean. Both RV EDV and RV ESV were decreased, but RV EF had an increased trend in untreated compared to lean rats. Macitentan‐treated rats did not show any significant changes compared to untreated Zucker <em>fa/fa</em> rats (Figure <a href="#fcp70006-fig-0002" class="usa-link">2</a>, upper panels).</p>
<figure class="fig xbox font-sm" id="fcp70006-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f53e/11981691/7ee55bf3c241/FCP-39-0-g005.jpg" loading="lazy" id="jats-graphic-5" height="810" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70006-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>
<strong>Right ventricular function. Upper panel</strong>. Right ventricular (RV) ejection fraction (EF), RV end‐diastolic volume (RV EDV), RV end‐systolic volume (RV ESV) and cardiac output obtained by MRI in 13 week‐old lean (<em>n</em> = 11; white bars) and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 14; grey bars) or treated for 7 days with macitentan (<em>n</em> = 14; down‐hatched bars). <strong>Lower panel</strong>. RV EF, RV EDV, RV ESV and cardiac output obtained by MRI in 24 week‐old lean (<em>n</em> = 8; white bars), and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 10; grey bars) or treated for 90 days with macitentan (<em>n</em> = 10; down‐hatched bars). *: <em>P</em> &lt; 0.05 versus lean; †: <em>P</em> &lt; 0.05 versus untreated Zucker <em>fa/fa</em>.</p></figcaption></figure><p>Study 2: In 90‐day untreated Zucker <em>fa/fa</em> rats, RV EF, EDV and CO were significantly decreased but RV ESV was unchanged. Macitentan treatment led to significantly increased RV EF and RV EDV, consequently increasing CO compared to untreated Zucker <em>fa/fa</em> rats (Figure <a href="#fcp70006-fig-0002" class="usa-link">2</a>, lower panels). RV ESV after macitentan treatment was significantly decreased compared to the untreated group.</p>
<p>Study 2: In the 90‐day study, RV haemodynamics (Figure <a href="#fcp70006-fig-0003" class="usa-link">3</a>) showed that untreated rats had a significant increase in RV ESP, RV dP/dt<sub>min</sub> and RV Tau compared to lean and an increased trend for RV EDP and RV dP/dt<sub>max</sub>. Macitentan treatment significantly decreased RV ESP and a decreased trend for RV EDP compared to untreated. Moreover, macitentan significantly decreased RV dP/dt<sub>min</sub> and RV Tau and a reduced trend for RV dP/dt<sub>max</sub>.</p>
<figure class="fig xbox font-sm" id="fcp70006-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f53e/11981691/8793a5f974f6/FCP-39-0-g006.jpg" loading="lazy" id="jats-graphic-7" height="306" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70006-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>
<strong>Right ventricular haemodynamics</strong>. Right ventricular (RV) end‐systolic pressure (ESP), RV end‐diastolic pressure (EDP), as well as RV dP/dt<sub>max</sub> and dP/dt<sub>min</sub> and RV relaxation constant Tau determined in 24 week‐old lean rats (<em>n</em> = 9; white bars), and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 9; grey bars) or treated for 90 days with macitentan (<em>n</em> = 7; down‐hatched bars). *: <em>P</em> &lt; 0.05 versus lean; †: <em>P</em> &lt; 0.05 versus untreated Zucker <em>fa/fa</em>.</p></figcaption></figure></section><section id="fcp70006-sec-0026"><h3 class="pmc_sec_title">3.3. LV function and haemodynamics</h3>
<ul id="fcp70006-list-0003" class="list" style="list-style-type:none">
<li id="fcp70006-li-0058">
<span class="long-label">Study 1:</span><p>Regarding LV function, compared to lean, 7‐day untreated Zucker <em>fa/fa</em> rats showed no significant differences in terms of LV EF, LV EDV, LV ESV or CO (Figure <a href="#fcp70006-fig-0004" class="usa-link">4</a>, upper panels). Macitentan treatment significantly increased LV EF and decreased LV ESV but did not significantly modify LV EDV or CO (Figure <a href="#fcp70006-fig-0004" class="usa-link">4</a>, upper panels) compared to untreated.</p>
</li>
<li id="fcp70006-li-0059">
<span class="long-label">Study 2:</span><p>LV function in 90‐day untreated Zucker rats compared to lean, displayed a significant decrease in LV EDV, LV ESV and CO without modification of LV EF (Figure <a href="#fcp70006-fig-0004" class="usa-link">4</a>, lower panels), demonstrating HFpEF characteristics. Macitentan treatment showed slight increased trends but did not significantly change the functional parameters investigated (Figure <a href="#fcp70006-fig-0004" class="usa-link">4</a>, lower panels).</p>
</li>
<li id="fcp70006-li-0060">
<span class="long-label">Study 1:</span><p>Concerning LV haemodynamics, in 7‐day untreated Zucker <em>fa/fa</em> rats, LV; ESP, ESPVR, EDP, Tau and EDPVR were significantly increased compared to the lean controls (Figure <a href="#fcp70006-fig-0005" class="usa-link">5</a>; upper panels). Macitentan 7‐day treatment significantly reduced LV; ESP, EDP, Tau and EDPVR but did not modify LV ESPVR (Figure <a href="#fcp70006-fig-0005" class="usa-link">5</a>; upper panels).</p>
</li>
<li id="fcp70006-li-0061">
<span class="long-label">Study 2:</span><p>For LV haemodynamics in 90‐day untreated Zucker <em>fa/fa</em> rats, LV; ESP, EDP and EDPVR were significantly increased, but LV, ESPVR and Tau were unchanged compared to lean (Figure <a href="#fcp70006-fig-0005" class="usa-link">5</a>, lower panels). Macitentan 90‐day treatment significantly decreased LV; ESP, EDP, EDPVR but did not modify LV; Tau or ESPVR (Figure <a href="#fcp70006-fig-0005" class="usa-link">5</a>; lower panels).</p>
</li>
</ul>
<figure class="fig xbox font-sm" id="fcp70006-fig-0004"><h4 class="obj_head">FIGURE 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f53e/11981691/b59762f18b85/FCP-39-0-g002.jpg" loading="lazy" id="jats-graphic-9" height="765" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70006-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>
<strong>Left ventricular function analysis by MRI. Upper panel</strong>. Left ventricular (LV) ejection fraction (EF), LV end‐diastolic volume (LV EDV), LV end‐systolic volume (LV ESV) and cardiac output obtained by MRI in 13 week‐old lean (<em>n</em> = 9; white bars) and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 11; grey bars) or treated for 7 days with macitentan (<em>n</em> = 13; down‐hatched bars).<strong>Lower panel</strong>. LV EF, LV EDV, LV ESV and cardiac output obtained by MRI in 24 week‐old lean (<em>n</em> = 9; white bars) and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 11; grey bars) or treated for 90 days with macitentan (<em>n</em> = 12; down‐hatched bars).*: <em>P</em> &lt; 0.05 versus lean; †: <em>P</em> &lt; 0.05 versus untreated Zucker <em>fa/fa</em>.</p></figcaption></figure><figure class="fig xbox font-sm" id="fcp70006-fig-0005"><h4 class="obj_head">FIGURE 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f53e/11981691/10d4f9ce08c1/FCP-39-0-g003.jpg" loading="lazy" id="jats-graphic-11" height="634" width="709" alt="FIGURE 5"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70006-fig-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>
<strong>Left ventricular haemodynamics. Upper panel</strong>. Left ventricular (LV) end‐systolic pressure (ESP), LV end‐systolic pressure‐volume relationship (ESPVR), LV end‐diastolic pressure (EDP) and LV end‐diastolic pressure‐volume relationship (EDPVR) determined in 13 week‐old lean rats (<em>n</em> = 6; white bars) and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 9; grey bars) or treated for 7 days with macitentan (<em>n</em> = 9; down‐hatched bars). <strong>Lower panel</strong> LV ESP, LV ESPVR, LV EDP and LV EDPVR determined in 24 week‐old lean rats (<em>n</em> = 6; white bars), and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 9; grey bars) or treated for 90 days with macitentan (<em>n</em> = 9; down‐hatched bars). *: <em>P</em> &lt; 0.05 versus lean; †: <em>P</em> &lt; 0.05 versus untreated Zucker <em>fa/fa</em>.</p></figcaption></figure></section><section id="fcp70006-sec-0027"><h3 class="pmc_sec_title">3.4. Right and septal coronary vascular function</h3>
<p>RV coronary function: RV coronary endothelium‐dependent relaxation to acetylcholine both in 7‐ and 90‐day untreated and treated rats did not show a significant difference to their respective controls (Figure <a href="#fcp70006-fig-0006" class="usa-link">6</a>; upper panel and Table <a href="#fcp70006-supitem-0001" class="usa-link">S2</a>).</p>
<figure class="fig xbox font-sm" id="fcp70006-fig-0006"><h4 class="obj_head">FIGURE 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f53e/11981691/9391af259a88/FCP-39-0-g007.jpg" loading="lazy" id="jats-graphic-13" height="903" width="709" alt="FIGURE 6"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70006-fig-0006/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>
<strong>Right ventricular and left ventricular coronary endothelium‐dependent relaxation. Upper panel</strong>. Right ventricular (RV) (upper panel) and left ventricular (LV) (lower panel) coronary relaxation induced by acetylcholine in 13 and 24 week‐old lean rats (<em>n</em> = 6 and <em>n</em> = 4, respectively; white circles) and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 4 and <em>n</em> = 6, respectively; black circles) or treated for 7 or 90 days, respectively, with macitentan (<em>n</em> = 5 and <em>n</em> = 8 respectively black triangles). <strong>Lower panel</strong>. Left ventricular (LV) (lower panel) coronary relaxation induced by acetylcholine in 13‐ and 24‐week‐old lean rats (<em>n</em> = 4 and <em>n</em> = 4, respectively; white circles) and Zucker <em>fa/fa</em> rats either untreated (<em>n</em> = 6 and <em>n</em> = 6, respectively; black circles) or treated for 7 or 90 days, respectively, with macitentan (<em>n</em> = 8 and <em>n</em> = 7, respectively black triangles). *: <em>P</em> &lt; 0.05 versus lean; †: <em>P</em> &lt; 0.05 versus untreated Zucker <em>fa/fa</em>.</p></figcaption></figure><p>LV coronary function: Untreated 7‐ and 90‐day Zucker <em>fa/fa</em> rats demonstrated an impairment of acetylcholine‐induced relaxation of LV coronary artery when compared respective lean controls. Macitentan 7‐ and 90‐day treatment restored or prevented this impairment in LV coronary relaxation compared to respective untreated groups (Figure <a href="#fcp70006-fig-0006" class="usa-link">6</a> and Table <a href="#fcp70006-supitem-0001" class="usa-link">S2</a>).</p></section><section id="fcp70006-sec-0028"><h3 class="pmc_sec_title">3.5. RV and LV morphology</h3>
<ul id="fcp70006-list-0004" class="list" style="list-style-type:none">
<li id="fcp70006-li-0062">
<span class="long-label">Study 1:</span><p>RV and LV weights were unchanged in 7‐day untreated Zucker rats; however, cardiomyocyte size and collagen deposition were significantly increased compared to lean. Moreover, LV perfusion, LV macrophage type‐1 nor type‐2 was not modified, but LV ROS was significantly increased and RV ROS had an increased trend in untreated compared to lean. Macitentan treatment significantly decreased LV and RV ROS and LV macrophages and increased myocardial perfusion compared to untreated (Table <a href="#fcp70006-tbl-0001" class="usa-link">1</a>). Macitentan treatment did not change the other parameters measured compared to untreated.</p>
</li>
<li id="fcp70006-li-0063">
<span class="long-label">Study 2:</span><p>In 90‐day untreated Zucker rats, RV weight, RV ROS and LV macrophages were not modified, but LV, weight, cardiomyocyte size, ROS and collagen were significantly increased, while myocardial perfusion was decreased compared to lean rats. Macitentan treatment significantly decreased LV; collagen density, ROS and macrophages and increased myocardial perfusion compared to untreated but other parameters were unchanged (Table <a href="#fcp70006-tbl-0001" class="usa-link">1</a>).</p>
</li>
</ul>
<section class="tw xbox font-sm" id="fcp70006-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Body weight, right and left ventricular characteristics.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1"></th>
<th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Time</th>
<th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Lean</th>
<th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Zucker <em>fa/fa</em>
</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Untreated</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Macitentan</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Body weight (g)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">383 ± 18</td>
<td align="center" valign="top" rowspan="1" colspan="1">474 ± 11<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">451 ± 11</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">437 ± 13</td>
<td align="center" valign="top" rowspan="1" colspan="1">519 ± 16<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">496 ± 16</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>RV Weight (mg)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">190 ± 15</td>
<td align="center" valign="top" rowspan="1" colspan="1">214 ± 10</td>
<td align="center" valign="top" rowspan="1" colspan="1">201 ± 15</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">242 ± 12</td>
<td align="center" valign="top" rowspan="1" colspan="1">261 ± 22</td>
<td align="center" valign="top" rowspan="1" colspan="1">274 ± 11</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>RV ROS (AU)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">68 ± 6</td>
<td align="center" valign="top" rowspan="1" colspan="1">83 ± 8</td>
<td align="center" valign="top" rowspan="1" colspan="1">63 ± 5<a href="#fcp70006-note-0005" class="usa-link">
<sup>†</sup>
</a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">112 ± 9</td>
<td align="center" valign="top" rowspan="1" colspan="1">120 ± 11</td>
<td align="center" valign="top" rowspan="1" colspan="1">114 ± 11</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV weight (mg)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">759 ± 36</td>
<td align="center" valign="top" rowspan="1" colspan="1">831 ± 36</td>
<td align="center" valign="top" rowspan="1" colspan="1">792 ± 26</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">790 ± 017</td>
<td align="center" valign="top" rowspan="1" colspan="1">881 ± 22<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">879 ± 18</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV myocyte size (μm</strong>
<sup>
<strong>2</strong>
</sup>
<strong>)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">453 ± 17</td>
<td align="center" valign="top" rowspan="1" colspan="1">507 ± 30<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">485 ± 52</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">477 ± 20</td>
<td align="center" valign="top" rowspan="1" colspan="1">561 ± 43<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">556 ± 31</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV collagen (%)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.87 ± 0.09</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.05 ± 0.05<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.01 ± 0.04</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.93 ± 0.10</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.32 ± 0.13<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.76 ± 0.06<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV perfusion (ml/min/g)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">11.0 ± 0.6</td>
<td align="center" valign="top" rowspan="1" colspan="1">10.2 ± 0.3</td>
<td align="center" valign="top" rowspan="1" colspan="1">11.1 ± 0.3†</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">9.5 ± 0.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">7.9 ± 0.4<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">8.8 ± 0.2<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV capillary density (nb/mm</strong>
<sup>
<strong>2</strong>
</sup>
<strong>)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">2572 ± 87</td>
<td align="center" valign="top" rowspan="1" colspan="1">2386 ± 100</td>
<td align="center" valign="top" rowspan="1" colspan="1">2479 ± 86</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">2286 ± 158</td>
<td align="center" valign="top" rowspan="1" colspan="1">2020 ± 171</td>
<td align="center" valign="top" rowspan="1" colspan="1">2143 ± 180</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV ROS (AU/g/min)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">129 ± 6</td>
<td align="center" valign="top" rowspan="1" colspan="1">154 ± 9<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">125 ± 3<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">370 ± 55</td>
<td align="center" valign="top" rowspan="1" colspan="1">620 ± 66<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">479 ± 58<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV macrophage type‐1 (nb/field)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.83 ± 0.57</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.96 ± 0.20</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.27 ± 0.19<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.47 ± 0.58</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.42 ± 0.40</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.17 ± 0.11<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>LV macrophage type‐2 (nb/field)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.63 ± 0.83</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.23 ± 0.18</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.50 ± 0.26<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.24 ± 0.37</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.48 ± 0.69</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.08 ± 0.60</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Ratio M1 to M2</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.53 ± 0.65</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.06 ± 0.34</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.24 ± 0.19<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.75 ± 0.28</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.24 ± 0.77</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.07 ± 0.04<a href="#fcp70006-note-0005" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Pulmonary weight (g)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.309 ± 0.056</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.094 ± 0.032<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.065 ± 0.030</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.374 ± 0.0439</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.264 ± 0.025<a href="#fcp70006-note-0004" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.146 ± 0.049</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/fcp70006-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="fcp70006-note-0002"><p>
<em>Note</em>: Histological analysis, capillary density, ROS, LV perfusion and macrophage measurements (D<sub>7</sub>: lean <em>n</em> = 10, untreated <em>n</em> = 6 and treated <em>n</em> = 6, D<sub>90</sub>: lean <em>n</em> = 8, untreated <em>n</em> = 9 and treated <em>n</em> = 8). Body weight, RV and LV weight and pulmonary weight (D<sub>7</sub>: lean <em>n</em> = 7, untreated <em>n</em> = 10 and treated <em>n</em> = 10, D<sub>90</sub>: lean <em>n</em> = 11, untreated <em>n</em> = 10 and treated <em>n</em> = 9).</p></div>
<div class="fn" id="fcp70006-note-0003"><p>Abbreviations: AU, arbitrary units; LV, Left ventricular; ROS, reactive oxygen species; RV, right ventricular.</p></div>
<div class="fn" id="fcp70006-note-0004">
<sup>*</sup><p class="display-inline">: <em>p</em> &lt; 0.05 versus lean.</p>
</div>
<div class="fn" id="fcp70006-note-0005">
<sup>†</sup><p class="display-inline">: <em>P</em> &lt; 0.05 vs untreated Zucker <em>fa/fa</em>.</p>
</div>
</div></section></section><section id="fcp70006-sec-0029"><h3 class="pmc_sec_title">3.6. ET<sub>A</sub>‐ET<sub>B</sub> receptor blockade</h3>
<ul id="fcp70006-list-0005" class="list" style="list-style-type:none">
<li id="fcp70006-li-0064">
<span class="long-label">Study 1:</span><p>The ET‐1 injection led to a transient blood pressure reduction followed by a sustained blood pressure increase (−39.3 and +18.0 mmHg compared to baseline) in 7‐day untreated rats (Table <a href="#fcp70006-tbl-0002" class="usa-link">2</a>). Macitentan administration for 7 days abolished ET‐1‐related blood pressure variations.</p>
</li>
<li id="fcp70006-li-0065">
<span class="long-label">Study 2:</span><p>After ET‐1 injection there was a transient blood pressure reduction followed by a sustained blood pressure increase (−41.9 and +16.5 mmHg compared to baseline) in 90‐day untreated rats. Macitentan treatment prevented ET‐1‐related blood pressure variations.</p>
</li>
</ul>
<section class="tw xbox font-sm" id="fcp70006-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>ET<sub>A</sub>‐ET<sub>B</sub> receptor blockade assessment.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1"></th>
<th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Time</th>
<th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Zucker <em>fa/fa</em>
</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Untreated</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Macitentan</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Transient systolic blood pressure decrease (mm Hg)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">−39.3 ± 0.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">−4.4 ± 0.7<a href="#fcp70006-note-0007" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">−41.9 ± 4.9</td>
<td align="center" valign="top" rowspan="1" colspan="1">−1.7 ± 1.1<a href="#fcp70006-note-0007" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Sustained systolic blood pressure increase (mm Hg)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">18.0 ± 1.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.8 ± 1.4<a href="#fcp70006-note-0007" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">16.5 ± 2.8</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.0 ± 1.0<a href="#fcp70006-note-0007" class="usa-link"><sup>†</sup></a>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/fcp70006-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="fcp70006-note-0006"><p>Blood pressure assessment after IV endothelin‐1 bolus administration (1 nmol.kg<sup>−1</sup>) (For each group <em>n</em> = 3).</p></div>
<div class="fn" id="fcp70006-note-0007">
<sup>†</sup><p class="display-inline">: <em>P</em> &lt; 0.05 vs untreated Zucker fa/fa.</p>
</div>
</div></section></section><section id="fcp70006-sec-0030"><h3 class="pmc_sec_title">3.7. Biomarkers</h3>
<ul id="fcp70006-list-0006" class="list" style="list-style-type:none">
<li id="fcp70006-li-0066">
<span class="long-label">Study 1:</span><p>Regarding metabolic characteristics, plasma triglycerides, HDL‐C, Galectin‐3 and NT‐ProBNP were increased in 7‐day untreated Zucker <em>fa/fa</em> rats but LCL‐C, ET‐1, creatinine and albumin were unchanged compared to lean (Table <a href="#fcp70006-tbl-0001" class="usa-link">1</a>). Macitentan treatment reduced plasma NT‐ProBNP and increased ET‐1 without modifying other biological parameters in the plasma compared to untreated.</p>
</li>
<li id="fcp70006-li-0067">
<span class="long-label">Study 2:</span><p>Untreated 90‐day rats had increased plasma triglycerides, HDL‐C, Galectin‐3 and NT‐ProBNP compared lean rats, but albumin, ET‐1, creatinine and LDL‐C were unchanged (Table <a href="#fcp70006-tbl-0003" class="usa-link">3</a>). Albuminuria was increased in 90‐day untreated rats, while creatininuria was decreased. Macitentan 90‐day treatment increased LDL‐C and ET‐1 but reduced plasma triglycerides, NT‐ProBNP and albuminuria compared to untreated.</p>
</li>
</ul>
<section class="tw xbox font-sm" id="fcp70006-tbl-0003"><h4 class="obj_head">TABLE 3.</h4>
<div class="caption p"><p>Plasma and urinary biology.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1"></th>
<th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Time</th>
<th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Lean</th>
<th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Zucker <em>fa/fa</em>
</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Untreated</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Macitentan</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma Triglycerides (mg/dL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">103 ± 16</td>
<td align="center" valign="top" rowspan="1" colspan="1">256 ± 49<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">312 ± 18</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">119 ± 13</td>
<td align="center" valign="top" rowspan="1" colspan="1">406 ± 40<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">264 ± 25<a href="#fcp70006-note-0011" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma HDL‐C (mg/dL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">56 ± 2.9</td>
<td align="center" valign="top" rowspan="1" colspan="1">91.3 ± 5.7<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">102.8 ± 7.9</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">62 ± 3.3</td>
<td align="center" valign="top" rowspan="1" colspan="1">109.0 ± 5.0<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">117.3 ± 3.4</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma LDL‐C (mg/dL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">23.2 ± 1.5</td>
<td align="center" valign="top" rowspan="1" colspan="1">21.9 ± 4.4</td>
<td align="center" valign="top" rowspan="1" colspan="1">23.4 ± 1.7</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">32.7 ± 4.1</td>
<td align="center" valign="top" rowspan="1" colspan="1">43.4 ± 4.3</td>
<td align="center" valign="top" rowspan="1" colspan="1">56.2 ± 4.4<a href="#fcp70006-note-0011" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma albumin (g/dL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.97 ± 0.06</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.16 ± 0.12</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.32 ± 0.09</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.00 ± 0.10</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.80 ± 0.14</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.74 ± 0.11</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma ET‐1 (pg/mL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.9 ± 0.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.3 ± 0.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.5 ± 0.3 <a href="#fcp70006-note-0011" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.7 ± 0.1</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.8 ± 0.1</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.3 ± 0.2 <a href="#fcp70006-note-0011" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma NT‐proBNP (pg/mL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">70 ± 12</td>
<td align="center" valign="top" rowspan="1" colspan="1">167 ± 44<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">55 ± 20<a href="#fcp70006-note-0011" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">61 ± 11</td>
<td align="center" valign="top" rowspan="1" colspan="1">257 ± 5<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">26 ± 4<a href="#fcp70006-note-0011" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma galectin‐3 (ng/mL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3.5 ± 0.7</td>
<td align="center" valign="top" rowspan="1" colspan="1">6.4 ± 1.2<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">7.5 ± 1.3</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.9 ± 0.2</td>
<td align="center" valign="top" rowspan="1" colspan="1">14.3 ± 1.7<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">14.7 ± 1.9</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Plasma creatinine (mg/dL)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.43 ± 0.02</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.47 ± 0.04</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.41 ± 0.03</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.46 ± 0.02</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.47 ± 0.02</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.49 ± 0.01</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Urinary creatinine (μM/24 h)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">‐</td>
<td align="center" valign="top" rowspan="1" colspan="1">‐</td>
<td align="center" valign="top" rowspan="1" colspan="1">‐</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.23 ± 0.05</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.08 ± 0.05<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.95 ± 0.12</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>Urinary albumin (mg/24 h)</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">‐</td>
<td align="center" valign="top" rowspan="1" colspan="1">‐</td>
<td align="center" valign="top" rowspan="1" colspan="1">‐</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">169 ± 40</td>
<td align="center" valign="top" rowspan="1" colspan="1">633 ± 119<a href="#fcp70006-note-0010" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">387 ± 85<a href="#fcp70006-note-0011" class="usa-link"><sup>†</sup></a>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/fcp70006-tbl-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="fcp70006-note-0008"><p>
<em>Note</em>: Plasma level of molecules in lean and Zucker <em>fa/fa</em> rats either untreated or treated with macitentan (Plasma; D<sub>7</sub>: lean <em>n</em> = 7, untreated <em>n</em> = 4 and treated <em>n</em> = 4, D<sub>90</sub>: lean <em>n</em> = 6, untreated <em>n</em> = 12 and treated <em>n</em> = 13. Urine; D<sub>90</sub>: lean <em>n</em> = 8, untreated <em>n</em> = 7 and treatment <em>n</em> = 7).</p></div>
<div class="fn" id="fcp70006-note-0009"><p>Abbreviation: ET‐1, endothelin‐1.</p></div>
<div class="fn" id="fcp70006-note-0010">
<sup>*</sup><p class="display-inline">: <em>P</em> &lt; 0.05 versus lean.</p>
</div>
<div class="fn" id="fcp70006-note-0011">
<sup>†</sup><p class="display-inline">: <em>P</em> &lt; 0.05 versus untreated Zucker <em>fa/fa</em>.</p>
</div>
</div></section></section><section id="fcp70006-sec-0031"><h3 class="pmc_sec_title">3.8. Cardiac genes expression</h3>
<ul id="fcp70006-list-0007" class="list" style="list-style-type:none">
<li id="fcp70006-li-0068">
<span class="long-label">Study 1:</span><p>No changes were seen between the groups for the 7‐day study.</p>
</li>
<li id="fcp70006-li-0069">
<span class="long-label">Study 2:</span><p>LV tissue <em>Bnp</em> mRNA expression was increased in 90‐day untreated rats compared to lean, while <em>Anp</em> and <em>Nox4</em> expression was reduced, and <em>Sod2</em>, <em>Sod1</em> and <em>Xanthine oxidase</em> expressions were unchanged (Table <a href="#fcp70006-tbl-0004" class="usa-link">4</a>). Macitentan decreased <em>Bnp</em> and <em>Nox4</em>, which is essential in T2DM‐related cardiac inflammation and increased <em>Sod2</em> compared to untreated.</p>
</li>
</ul>
<section class="tw xbox font-sm" id="fcp70006-tbl-0004"><h4 class="obj_head">TABLE 4.</h4>
<div class="caption p"><p>LV genetic expression.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<col align="char" char="±" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Gene</th>
<th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Time</th>
<th rowspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Lean</th>
<th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Zucker <em>fa/fa</em>
</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Untreated</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Macitentan</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>
<em>Anp</em>
</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.26 ± 0.12</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.09 ± 0.16</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.03 ± 0.18</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.46 ± 0.08</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.25 ± 0.04<a href="#fcp70006-note-0013" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.32 ± 0.04</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>
<em>Bnp</em>
</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.33 ± 0.15</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.35 ± 0.14</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.09 ± 0.07</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.05 ± 0.13</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.84 ± 0.23<a href="#fcp70006-note-0013" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.03 ± 0.13<a href="#fcp70006-note-0014" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>
<em>Sod2</em>
</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.38 ± 0.10</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.58 ± 0.17</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.55 ± 0.14</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.30 ± 0.06</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.19 ± 0.06</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.32 ± 0.01<a href="#fcp70006-note-0014" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>
<em>Sod1</em>
</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.08 ± 0.07</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.26 ± 0.14</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.17 ± 0.04</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.78 ± 0.09</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.78 ± 0.13</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.79 ± 0.06</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>
<em>Nox4</em>
</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.89 ± 0.08</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.14 ± 0.08</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.03 ± 0.10</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.27 ± 0.14</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.70 ± 0.05<a href="#fcp70006-note-0013" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.56 ± 0.04<a href="#fcp70006-note-0014" class="usa-link"><sup>†</sup></a>
</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">
<strong>
<em>Xanthine oxidase</em>
</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>7</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.88 ± 0.12</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.04 ± 0.11</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.06 ± 0.14</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">D<sub>90</sub>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.82 ± 0.04</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.07 ± 0.16</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.95 ± 0.07</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/fcp70006-tbl-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="fcp70006-note-0012"><p>
<em>Note</em>: Cardiac relative expression of various mRNA in lean and Zucker <em>fa/fa</em> rats either untreated of treated with macitentan assessed by real‐time quantitative PCR and normalized to three housekeeping genes (GAPDH. tubulin. EEF2) (D<sub>7</sub>: lean <em>n</em> = 5, untreated <em>n</em> = 7 and treated <em>n</em> = 8, D<sub>90</sub>: lean <em>n</em> = 4, untreated <em>n</em> = 6 and treated <em>n</em> = 6).</p></div>
<div class="fn" id="fcp70006-note-0013">
<sup>*</sup><p class="display-inline">: <em>p</em> &lt; 0.05 versus lean.</p>
</div>
<div class="fn" id="fcp70006-note-0014">
<sup>†</sup><p class="display-inline">: <em>p</em> &lt; 0.05 versus untreated Zucker <em>fa/fa</em>.</p>
</div>
</div></section></section></section><section id="fcp70006-sec-0032"><h2 class="pmc_sec_title">4. DISCUSSION</h2>
<p>This study highlights that obese Zucker <em>fa/fa</em> rats, which are a rat model of MetS, develop HFpEF gradually alongside LV and RV diastolic dysfunctions and characteristics of PH. The efficacy of macitentan in this model confirms the involvement of ET‐1 and its receptors in the deleterious progression of this phenotype. We also found endothelial dysfunction in coronary arteries from obese Zucker rats, in line with other publications [<a href="#fcp70006-bib-0046" class="usa-link" aria-describedby="fcp70006-bib-0046">46</a>, <a href="#fcp70006-bib-0047" class="usa-link" aria-describedby="fcp70006-bib-0047">47</a>].</p>
<p>The obese Zucker <em>fa/fa</em> rat is an already well‐characterized model of MetS and HF, and our data provide evidence that it can be used as a model HFpEF associated with PH [<a href="#fcp70006-bib-0048" class="usa-link" aria-describedby="fcp70006-bib-0048">48</a>, <a href="#fcp70006-bib-0049" class="usa-link" aria-describedby="fcp70006-bib-0049">49</a>, <a href="#fcp70006-bib-0050" class="usa-link" aria-describedby="fcp70006-bib-0050">50</a>]. Although a limitation of this model is that it is not always associated with hypertension, from our results it appears that our Zucker <em>fa/fa</em> rat model mimics the association of PH, LV and RV dysfunctions observed in humans with HFpEF without or associated with MetS [<a href="#fcp70006-bib-0051" class="usa-link" aria-describedby="fcp70006-bib-0051">51</a>, <a href="#fcp70006-bib-0052" class="usa-link" aria-describedby="fcp70006-bib-0052">52</a>, <a href="#fcp70006-bib-0053" class="usa-link" aria-describedby="fcp70006-bib-0053">53</a>]. Moreover, our results clearly demonstrate that ET‐1 is involved is the development of RV, LV and vascular dysfunctions observed in obese Zucker <em>fa/fa</em> rats since both 7‐ and 90‐day treatments with macitentan improved blood composition, cardiac and vascular functions. The plasma biology showed that macitentan increases plasma ET‐1 at both time points confirming the blockade and decreases in plasma NT‐proBNP showing improved cardiovascular function. Ninety‐day treatment showed more biochemical improvements in the plasma and urine with decreased levels of LCL‐C, triglycerides and urinary albumin, suggesting long‐term treatment may be the most beneficial. The ability of the macitentan 10 mg/kg/day dose, in accordance to previous macitentan studies, to block ET<sub>A</sub> and ET<sub>B</sub> receptors was confirmed in our study since this dose (1) prevented ET‐1‐induced biphasic response: ET<sub>B</sub>‐mediated blood pressure decrease, and ET<sub>A</sub>‐mediated blood pressure increase changes and (2) increased ET‐1 plasma concentrations, which confirms the functional blockade of ET receptors, in agreement with other studies [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>, <a href="#fcp70006-bib-0012" class="usa-link" aria-describedby="fcp70006-bib-0012">12</a>, <a href="#fcp70006-bib-0054" class="usa-link" aria-describedby="fcp70006-bib-0054">54</a>]. It could be considered a limitation that no dose–response experiments were performed in this study, but this has been performed previously, which provided sufficient data for our study without repeating the experiment [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>, <a href="#fcp70006-bib-0035" class="usa-link" aria-describedby="fcp70006-bib-0035">35</a>]. Although no dose–response experiments were performed in this study, the 10 mg/kg dose has been demonstrated to be the maximal effective dose in models of hypertension [<a href="#fcp70006-bib-0012" class="usa-link" aria-describedby="fcp70006-bib-0012">12</a>, <a href="#fcp70006-bib-0035" class="usa-link" aria-describedby="fcp70006-bib-0035">35</a>]. Macitentan at 10 mg/kg/day has been shown in current literature to cause a reduction in systolic BP and LV weight in a mouse HFpEF model, successful dual ERA action in rat models, the latter of which showed that an increased dose would not have a bigger therapeutic effect for hypertension [<a href="#fcp70006-bib-0009" class="usa-link" aria-describedby="fcp70006-bib-0009">9</a>, <a href="#fcp70006-bib-0012" class="usa-link" aria-describedby="fcp70006-bib-0012">12</a>, <a href="#fcp70006-bib-0054" class="usa-link" aria-describedby="fcp70006-bib-0054">54</a>]. We selected the estimated lowest possible dose for a therapeutic effect for our study from this literature. A limitation is that we cannot compare the potential effects of a higher dose in our study and this should be considered for future studies.</p>
<p>Although it is shown that ERAs may exert beneficial effects on PH and RV remodelling, clinical trials on LV failure with ERAs have been disappointing [<a href="#fcp70006-bib-0055" class="usa-link" aria-describedby="fcp70006-bib-0055">55</a>, <a href="#fcp70006-bib-0056" class="usa-link" aria-describedby="fcp70006-bib-0056">56</a>, <a href="#fcp70006-bib-0057" class="usa-link" aria-describedby="fcp70006-bib-0057">57</a>, <a href="#fcp70006-bib-0058" class="usa-link" aria-describedby="fcp70006-bib-0058">58</a>, <a href="#fcp70006-bib-0059" class="usa-link" aria-describedby="fcp70006-bib-0059">59</a>]. However, in the ENABLE study, death was non‐significantly lower in the bosentan‐treated group than in the placebo‐treated group at the end of the study (160 vs. 173 deaths) despite early fluid retention, while in experimental HF bosentan significantly improved long‐term survival [<a href="#fcp70006-bib-0059" class="usa-link" aria-describedby="fcp70006-bib-0059">59</a>, <a href="#fcp70006-bib-0060" class="usa-link" aria-describedby="fcp70006-bib-0060">60</a>]. Thus, our data, obtained in a rat model of HFpEF associated with RV dysfunction and PH characteristics, suggest that dual ERAs could exert beneficial effects on LV function and structure in Humans with HFpEF [<a href="#fcp70006-bib-0011" class="usa-link" aria-describedby="fcp70006-bib-0011">11</a>, <a href="#fcp70006-bib-0033" class="usa-link" aria-describedby="fcp70006-bib-0033">33</a>]. Furthermore, macitentan prevents the progression of HFpEF since, at the initiation of treatment; the model exhibited only early LV diastolic dysfunction with preserved systolic function and then developed RV systolic and diastolic dysfunction. Whether macitentan's beneficial effects on cardiac and vascular function are associated with an improvement of exercise capacity, described as reduced in this model, remains to be confirmed [<a href="#fcp70006-bib-0061" class="usa-link" aria-describedby="fcp70006-bib-0061">61</a>].</p>
<p>Our results show that at least two potential different mechanisms may be involved in the beneficial effects of ET receptor blockade. First, reduction of ET‐1–mediated vasoconstriction induces an immediate and a sustained reduction of systolic and diastolic BP and of LV EDPVR, potentially participating to the improvement of LV diastolic function [<a href="#fcp70006-bib-0023" class="usa-link" aria-describedby="fcp70006-bib-0023">23</a>]. This mechanism could also explain the decrease in RV ESP. Second, obesity but also ET‐1 are known to induce ROS production and ET‐1 blockade (Table <a href="#fcp70006-tbl-0002" class="usa-link">2</a>) resulted in reduced LV oxidative stress as observed by the reduction of ROS levels after both 7‐ and 90‐day treatment [<a href="#fcp70006-bib-0062" class="usa-link" aria-describedby="fcp70006-bib-0062">62</a>]. Furthermore, reducing ROS production and consequently oxidative stress could contribute to the improvement of LV diastolic function by enhancing LV relaxation. This could be due to oxidative stress involvement in abnormal Ca<sup>2+</sup> handling thus impairing cardiomyocyte relaxation [<a href="#fcp70006-bib-0063" class="usa-link" aria-describedby="fcp70006-bib-0063">63</a>]. ROS overproduction has also been associated with exaggerated collagen deposition, which is known to decrease cardiac compliance [<a href="#fcp70006-bib-0064" class="usa-link" aria-describedby="fcp70006-bib-0064">64</a>]. Hence, reduction of ROS levels by ET receptor blockade could partially explain the reduction of LV collagen deposition observed after 90‐day macitentan treatment (Table <a href="#fcp70006-tbl-0001" class="usa-link">1</a>). Overall, the prevention of cardiac fibrosis development strongly contributed to the improvement of LV function observed after 90‐day macitentan treatment, as observed with other drugs [<a href="#fcp70006-bib-0063" class="usa-link" aria-describedby="fcp70006-bib-0063">63</a>, <a href="#fcp70006-bib-0064" class="usa-link" aria-describedby="fcp70006-bib-0064">64</a>, <a href="#fcp70006-bib-0065" class="usa-link" aria-describedby="fcp70006-bib-0065">65</a>, <a href="#fcp70006-bib-0066" class="usa-link" aria-describedby="fcp70006-bib-0066">66</a>]. Another potential mechanism involved in the improvement of LV diastolic dysfunction could be an increase in nitric oxide (NO) bioavailability. This was suggested by our improved coronary relaxation results, which would need to be investigated further. Both experimental and clinical data demonstrate that NO donors or eNOS enhancers reduce LV diastolic dysfunction or LV remodelling [<a href="#fcp70006-bib-0067" class="usa-link" aria-describedby="fcp70006-bib-0067">67</a>]. Regarding redox activity, mRNA analysis showed an increase in <em>Sod2</em> expression and decreases in <em>Bnp</em> and <em>Nox4</em> expression showing protective effects but only after 90‐days of treatment. A limitation was that protein analysis was not performed, which would have provided a clearer explanation to the regulation of these proteins of interest.</p>
<p>Furthermore, drugs targeting ET function for patients with T2DM and HF have been investigated to treat both conditions, for example, SGLT2i showed an improvement in ET flow‐mediated dilation [<a href="#fcp70006-bib-0068" class="usa-link" aria-describedby="fcp70006-bib-0068">68</a>]. SGLT2i work by lowering glucose uptake, causing glycosuria, which may improve HF outcomes due to metabolic changes; however; further investigation is required [<a href="#fcp70006-bib-0069" class="usa-link" aria-describedby="fcp70006-bib-0069">69</a>]. Due to the difference in mechanisms of action, it would be beneficial to test in the future the effect of combined and comparative macitentan and SGLT2i HFpEF treatment.</p>
<p>Neprilysin inhibitors, which are used in the PARAGON HF clinical trial, have been investigated for T2DM treatment due to its effects on ET and its ability to increase lipolysis and lipid oxidation, which is a key component in glucose homeostasis [<a href="#fcp70006-bib-0070" class="usa-link" aria-describedby="fcp70006-bib-0070">70</a>]. This study showed an increase in both treatment time lengths in LV perfusion (Table <a href="#fcp70006-tbl-0001" class="usa-link">1</a>), restoration of endothelium relaxation and decrease in plasma triglycerides after 90‐day treatment (Table <a href="#fcp70006-tbl-0001" class="usa-link">1</a>). These results alongside the effect of macitentan on reducing BP (Figure <a href="#fcp70006-fig-0001" class="usa-link">1</a>) at both time points could be considered potentially beneficial for T2DM, which merits further investigation. Moreover, the reduction in ROS may contribute to the improvement of renal function induced by macitentan, illustrated by the reduction of albuminuria and Galectin‐3 levels at the end of the 90‐day treatment. The reduction of albuminuria after 90 days in HFpEF rats demonstrates that this could be a model of cardiorenal syndrome, which is improved by dual ET receptor blockade. Our model has been previously shown as a model of cardiorenal syndrome and MetS by measuring proteinuria which is reduced by finerenone treatment [<a href="#fcp70006-bib-0061" class="usa-link" aria-describedby="fcp70006-bib-0061">61</a>, <a href="#fcp70006-bib-0071" class="usa-link" aria-describedby="fcp70006-bib-0071">71</a>]. The effects may be due to more than direct ET receptor blockade alone as it could be the reduction in ROS, which is demonstrated when using drugs with a similar profile, for example, finerenone [<a href="#fcp70006-bib-0071" class="usa-link" aria-describedby="fcp70006-bib-0071">71</a>]. Another consideration of whether the mechanism of action of macitentan is direct or indirect is that imeglimin also reduces albuminuria after long‐term treatment; therefore, both drugs are likely to be slowing the progression of the kidney dysfunction, which warrants further investigation [<a href="#fcp70006-bib-0061" class="usa-link" aria-describedby="fcp70006-bib-0061">61</a>]. It must be noted for translatability that male rats only were used, which is a limitation and a key aim is that this study can provide suitable data for further study and male and female animals.</p>
<p>Furthermore, cardiac remodelling involves inflammation and ET‐1 itself exerts pro‐inflammatory actions [<a href="#fcp70006-bib-0072" class="usa-link" aria-describedby="fcp70006-bib-0072">72</a>]. This was interesting for the treatment of macitentan, which showed there was a reduction in the number of cardiac pro‐inflammatory M1 macrophages (Table <a href="#fcp70006-tbl-0001" class="usa-link">1</a>) after 90‐day treatment suggesting a decrease in inflammatory signals. This presents an interesting mechanism of decreasing the pro‐inflammatory effect of ET‐1 by ETR blockade [<a href="#fcp70006-bib-0073" class="usa-link" aria-describedby="fcp70006-bib-0073">73</a>]. ET<sub>B</sub> has been shown to be key in inflammation in various studies and in a mouse genetic knock‐out model of ET<sub>B</sub> [<a href="#fcp70006-bib-0073" class="usa-link" aria-describedby="fcp70006-bib-0073">73</a>, <a href="#fcp70006-bib-0074" class="usa-link" aria-describedby="fcp70006-bib-0074">74</a>, <a href="#fcp70006-bib-0075" class="usa-link" aria-describedby="fcp70006-bib-0075">75</a>, <a href="#fcp70006-bib-0076" class="usa-link" aria-describedby="fcp70006-bib-0076">76</a>]. While ET<sub>A</sub> is mainly expressed on the vascular smooth muscle cells (VSMC), leading to vasoconstriction, ET<sub>B</sub> is expressed in the endothelial cells and renal epithelial cells, and both receptors are expressed in the lungs [<a href="#fcp70006-bib-0023" class="usa-link" aria-describedby="fcp70006-bib-0023">23</a>, <a href="#fcp70006-bib-0077" class="usa-link" aria-describedby="fcp70006-bib-0077">77</a>]. Blocking both of these receptors may be a good solution for targeting inflammatory cardiac remodelling.</p></section><section id="fcp70006-sec-0033"><h2 class="pmc_sec_title">5. CONCLUSION</h2>
<p>In conclusion, in a rat model of HFpEF associated with PH and DM characteristics, dual ET receptor blockade reduced PH and improvement of cardiac and coronary functions. This suggests that dual ERAs, already used to treat isolated PH in humans, might also exert beneficial cardiac and vascular effects in HFpEF and thus seems to be a promising approach for HFpEF [<a href="#fcp70006-bib-0055" class="usa-link" aria-describedby="fcp70006-bib-0055">55</a>, <a href="#fcp70006-bib-0078" class="usa-link" aria-describedby="fcp70006-bib-0078">78</a>].</p></section><section id="fcp70006-sec-0034"><h2 class="pmc_sec_title">AUTHOR CONTRIBUTIONS</h2>
<p>
<em>Participated in research design</em>: Francesca Lockwood, Magali Vercauteren, Marc Iglarz and Vincent Richard, Mulder. <em>Conducted experiments</em>: Francesca Lockwood, Marianne Lachaux, Najah Harouki, Matthieu Soulié, Lionel Nicol, Sylvanie Renet, Anaïs Dumesnil and Magali Vercauteren. <em>Performed data analysis</em>: Francesca Lockwood, Marianne Lachaux, Najah Harouki, Matthieu Soulié, Lionel Nicol, Anaïs Dumesnil, Magali Vercauteren and Marc Iglarz. <em>Wrote or contributed to the writing of the manuscript</em>: Francesca Lockwood, Marianne Lachaux, Najah Harouki, Matthieu Soulié, Marc Iglarz, Jeremy Bellien, Vincent Richard and Paul Mulder.</p></section><section id="fcp70006-sec-0036"><h2 class="pmc_sec_title">CONFLICT OF INTEREST STATEMENT</h2>
<p>Francesca Lockwood, Marianne Lachaux, Najah Harouki, Matthieu Soulié, Lionel Nicol, Sylvanie Renet, Anais Dumesnil, Jeremy Bellien, Vincent Richard and Paul Mulder have no conflicts of interest. At the time of the experiments, Magali Vercauteren and Marc Iglarz were employed by Actelion Pharmaceuticals Ltd (Switzerland).</p></section><section id="sec36"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="fcp70006-supitem-0001"><div class="caption p">
<p>
<strong>Table S1.</strong> Blood pressure at 90 days numerical data.</p>
<p>
<strong>Table S2.</strong> Right and left ventricular coronary artery relaxation at 10<sup>–4.5</sup> M Acetylcholine numerical data.</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11981691/bin/FCP-39-0-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">FCP-39-0-s001.docx</a><sup> (18.3KB, docx) </sup>
</div></div></section></section><section id="fcp70006-sec-0035" class="ack"><h2 class="pmc_sec_title">ACKNOWLEDGEMENTS</h2>
<p>The authors thank Daniel Strasser and Herve Farine for their excellent technical assistance.</p></section><section id="notes1"><p>

Lockwood F, Lachaux M, Harouki N, et al. Dual ET<sub>A</sub>‐ET<sub>B</sub> receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction. Fundam Clin Pharmacol. 2025;39(3):e70006. doi: 10.1111/fcp.70006

</p>
<section id="fcp70006-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fcp70006-note-0001"><p>
<strong>Funding information</strong> Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, and co‐supported by the European Union and the Région Normandie. (Europe gets involved in Normandy with European Regional Development Fund; ERDF), the European Fibro‐Targets Project (grant agreement No. FP7#602904), the FP7‐funded COST ADMIRE network (BM1301) and the Fédération Française de Cardiologie. F Lockwood previously received Erasmus student funding and is currently a laureate of the WINNINGNormandy Marie Skłodowska‐Curie post‐doc fellowship (H2020‐MSCA‐COFUND‐2020, Marie Skłodowska‐Curie grant agreement No. 101034329).</p></div></div></section></section><section id="fcp70006-sec-0038"><h2 class="pmc_sec_title">DATA AVAILABILITY STATEMENT</h2>
<p>Further study data are available upon reasonable request to the corresponding author.</p></section><section id="fcp70006-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="fcp70006-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="fcp70006-bib-0001">
<span class="label">1.</span><cite>
Scuteri A, Laurent S, Cucca F, et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015;22(4):486‐491. doi: 10.1177/2047487314525529

</cite> [<a href="https://doi.org/10.1177/2047487314525529" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4544872/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24647805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Prev%20Cardiol&amp;title=Metabolic%20syndrome%20across%20Europe:%20different%20clusters%20of%20risk%20factors&amp;author=A%20Scuteri&amp;author=S%20Laurent&amp;author=F%20Cucca&amp;volume=22&amp;issue=4&amp;publication_year=2015&amp;pages=486-491&amp;pmid=24647805&amp;doi=10.1177/2047487314525529&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0002">
<span class="label">2.</span><cite>
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. doi: 10.1007/s11906-018-0812-z

</cite> [<a href="https://doi.org/10.1007/s11906-018-0812-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5866840/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29480368/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Hypertens%20Rep&amp;title=The%20global%20epidemic%20of%20the%20metabolic%20syndrome&amp;author=MG%20Saklayen&amp;volume=20&amp;issue=2&amp;publication_year=2018&amp;pages=12&amp;pmid=29480368&amp;doi=10.1007/s11906-018-0812-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0003">
<span class="label">3.</span><cite>
Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes Metab Res Rev. 2022;38(3):e3502. doi: 10.1002/dmrr.3502

</cite> [<a href="https://doi.org/10.1002/dmrr.3502" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34614543/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Metab%20Res%20Rev&amp;title=Metabolic%20syndrome%20and%20cardiovascular%20diseases:%20going%20beyond%20traditional%20risk%20factors&amp;author=JL%20Silveira%20Rossi&amp;author=SM%20Barbalho&amp;author=R%20Reverete%20de%20Araujo&amp;author=MD%20Bechara&amp;author=KP%20Sloan&amp;volume=38&amp;issue=3&amp;publication_year=2022&amp;pages=e3502&amp;pmid=34614543&amp;doi=10.1002/dmrr.3502&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0004">
<span class="label">4.</span><cite>
Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23(2):786. doi: 10.3390/ijms23020786

</cite> [<a href="https://doi.org/10.3390/ijms23020786" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8775991/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35054972/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Metabolic%20syndrome:%20updates%20on%20pathophysiology%20and%20management%20in%202021&amp;author=G%20Fahed&amp;author=L%20Aoun&amp;author=M%20Bou%20Zerdan&amp;volume=23&amp;issue=2&amp;publication_year=2022&amp;pages=786&amp;pmid=35054972&amp;doi=10.3390/ijms23020786&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0005">
<span class="label">5.</span><cite>
Tah S, Valderrama M, Afzal M, et al. Heart failure with preserved ejection fraction: an evolving understanding. Cureus. 2023;15(9):e46152. doi: 10.7759/cureus.46152

</cite> [<a href="https://doi.org/10.7759/cureus.46152" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10613100/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37900404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cureus&amp;title=Heart%20failure%20with%20preserved%20ejection%20fraction:%20an%20evolving%20understanding&amp;author=S%20Tah&amp;author=M%20Valderrama&amp;author=M%20Afzal&amp;volume=15&amp;issue=9&amp;publication_year=2023&amp;pages=e46152&amp;pmid=37900404&amp;doi=10.7759/cureus.46152&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0006">
<span class="label">6.</span><cite>
Correction to: 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2024;45(1):53. doi: 10.1093/eurheartj/ehad613

</cite> [<a href="https://doi.org/10.1093/eurheartj/ehad613" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37995350/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Correction%20to:%202023%20focused%20update%20of%20the%202021%20ESC%20guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure:%20developed%20by%20the%20task%20force%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure%20of%20the%20European%20Society%20of%20Cardiology%20(ESC)%20with%20the%20special%20contribution%20of%20the%20heart%20failure%20association%20(HFA)%20of%20the%20ESC&amp;volume=45&amp;issue=1&amp;publication_year=2024&amp;pages=53&amp;pmid=37995350&amp;doi=10.1093/eurheartj/ehad613&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0007">
<span class="label">7.</span><cite>
Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400‐423. doi: 10.1038/s41569-020-00480-6

</cite> [<a href="https://doi.org/10.1038/s41569-020-00480-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8574228/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33432192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cardiol&amp;title=Cellular%20and%20molecular%20pathobiology%20of%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;author=S%20Mishra&amp;author=DA%20Kass&amp;volume=18&amp;issue=6&amp;publication_year=2021&amp;pages=400-423&amp;pmid=33432192&amp;doi=10.1038/s41569-020-00480-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0008">
<span class="label">8.</span><cite>
Tourki B, Halade GV. Heart failure syndrome with preserved ejection fraction is a metabolic cluster of non‐resolving inflammation in obesity. Front Cardiovasc Med. 2021;8:695952. doi: 10.3389/fcvm.2021.695952

</cite> [<a href="https://doi.org/10.3389/fcvm.2021.695952" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8367012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34409075/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Cardiovasc%20Med&amp;title=Heart%20failure%20syndrome%20with%20preserved%20ejection%20fraction%20is%20a%20metabolic%20cluster%20of%20non%E2%80%90resolving%20inflammation%20in%20obesity&amp;author=B%20Tourki&amp;author=GV%20Halade&amp;volume=8&amp;publication_year=2021&amp;pages=695952&amp;pmid=34409075&amp;doi=10.3389/fcvm.2021.695952&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0009">
<span class="label">9.</span><cite>
Valero‐Munoz M, Li S, Wilson RM, Boldbaatar B, Iglarz M, Sam F. Dual endothelin‐A/endothelin‐B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(11):e003381. doi: 10.1161/CIRCHEARTFAILURE.116.003381

</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.116.003381" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5584628/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27810862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Heart%20Fail&amp;title=Dual%20endothelin%E2%80%90A/endothelin%E2%80%90B%20receptor%20blockade%20and%20cardiac%20remodeling%20in%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;author=M%20Valero%E2%80%90Munoz&amp;author=S%20Li&amp;author=RM%20Wilson&amp;author=B%20Boldbaatar&amp;author=M%20Iglarz&amp;volume=9&amp;issue=11&amp;publication_year=2016&amp;pages=e003381&amp;pmid=27810862&amp;doi=10.1161/CIRCHEARTFAILURE.116.003381&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0010">
<span class="label">10.</span><cite>
Khadka A, Singh Brashier DB, Tejus A, Sharma AK. Macitentan: an important addition to the treatment of pulmonary arterial hypertension. J Pharmacol Pharmacother. 2015;6(1):53‐57. doi: 10.4103/0976-500X.149151

</cite> [<a href="https://doi.org/10.4103/0976-500X.149151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4319253/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25709357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pharmacol%20Pharmacother&amp;title=Macitentan:%20an%20important%20addition%20to%20the%20treatment%20of%20pulmonary%20arterial%20hypertension&amp;author=A%20Khadka&amp;author=DB%20Singh%20Brashier&amp;author=A%20Tejus&amp;author=AK%20Sharma&amp;volume=6&amp;issue=1&amp;publication_year=2015&amp;pages=53-57&amp;pmid=25709357&amp;doi=10.4103/0976-500X.149151&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0011">
<span class="label">11.</span><cite>
Du D, Yuan YD. Efficacy and safety of macitentan for pulmonary hypertension: a meta‐analysis. Clin Respir J. 2023;17(11):1117‐1129. doi: 10.1111/crj.13621

</cite> [<a href="https://doi.org/10.1111/crj.13621" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10632077/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37427711/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Respir%20J&amp;title=Efficacy%20and%20safety%20of%20macitentan%20for%20pulmonary%20hypertension:%20a%20meta%E2%80%90analysis&amp;author=D%20Du&amp;author=YD%20Yuan&amp;volume=17&amp;issue=11&amp;publication_year=2023&amp;pages=1117-1129&amp;pmid=37427711&amp;doi=10.1111/crj.13621&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0012">
<span class="label">12.</span><cite>
Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue‐targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736‐745. doi: 10.1124/jpet.108.142976

</cite> [<a href="https://doi.org/10.1124/jpet.108.142976" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18780830/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pharmacol%20Exp%20Ther&amp;title=Pharmacology%20of%20macitentan,%20an%20orally%20active%20tissue%E2%80%90targeting%20dual%20endothelin%20receptor%20antagonist&amp;author=M%20Iglarz&amp;author=C%20Binkert&amp;author=K%20Morrison&amp;volume=327&amp;issue=3&amp;publication_year=2008&amp;pages=736-745&amp;pmid=18780830&amp;doi=10.1124/jpet.108.142976&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0013">
<span class="label">13.</span><cite>
Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, Pernow J. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia. 2012;55(3):600‐607. doi: 10.1007/s00125-011-2415-y

</cite> [<a href="https://doi.org/10.1007/s00125-011-2415-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22200728/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=The%20endothelin%20receptor%20antagonist%20bosentan%20improves%20peripheral%20endothelial%20function%20in%20patients%20with%20type%202%20diabetes%20mellitus%20and%20microalbuminuria:%20a%20randomised%20trial&amp;author=A%20Rafnsson&amp;author=F%20Bohm&amp;author=M%20Settergren&amp;author=A%20Gonon&amp;author=K%20Brismar&amp;volume=55&amp;issue=3&amp;publication_year=2012&amp;pages=600-607&amp;pmid=22200728&amp;doi=10.1007/s00125-011-2415-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0014">
<span class="label">14.</span><cite>
Zhou Y, Chi J, Huang Y, Dong B, Lv W, Wang YG. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta‐analysis of randomized controlled trials. Diabet Med. 2021;38(1):e14411. doi: 10.1111/dme.14411

</cite> [<a href="https://doi.org/10.1111/dme.14411" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33000477/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabet%20Med&amp;title=Efficacy%20and%20safety%20of%20endothelin%20receptor%20antagonists%20in%20type%202%20diabetic%20kidney%20disease:%20a%20systematic%20review%20and%20meta%E2%80%90analysis%20of%20randomized%20controlled%20trials&amp;author=Y%20Zhou&amp;author=J%20Chi&amp;author=Y%20Huang&amp;author=B%20Dong&amp;author=W%20Lv&amp;volume=38&amp;issue=1&amp;publication_year=2021&amp;pages=e14411&amp;pmid=33000477&amp;doi=10.1111/dme.14411&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0015">
<span class="label">15.</span><cite>
Smeijer JD, Gomez MF, Rossing P, Heerspink HJL. The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2024;27(2):511‐518. doi: 10.1111/dom.16041

</cite> [<a href="https://doi.org/10.1111/dom.16041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11701200/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39503150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=The%20effect%20of%20the%20endothelin%20receptor%20antagonist%20atrasentan%20on%20insulin%20resistance%20in%20phenotypic%20clusters%20of%20patients%20with%20type%202%20diabetes%20and%20chronic%20kidney%20disease&amp;author=JD%20Smeijer&amp;author=MF%20Gomez&amp;author=P%20Rossing&amp;author=HJL%20Heerspink&amp;volume=27&amp;issue=2&amp;publication_year=2024&amp;pages=511-518&amp;pmid=39503150&amp;doi=10.1111/dom.16041&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0016">
<span class="label">16.</span><cite>
Passarella P, Kiseleva TA, Valeeva FV, Gosmanov AR. Hypertension Management in Diabetes: 2018 Update. Diabetes Spectr. 2018;31(3):218‐224. doi: 10.2337/ds17-0085

</cite> [<a href="https://doi.org/10.2337/ds17-0085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6092891/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30140137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Spectr&amp;title=Hypertension%20Management%20in%20Diabetes:%202018%20Update&amp;author=P%20Passarella&amp;author=TA%20Kiseleva&amp;author=FV%20Valeeva&amp;author=AR%20Gosmanov&amp;volume=31&amp;issue=3&amp;publication_year=2018&amp;pages=218-224&amp;pmid=30140137&amp;doi=10.2337/ds17-0085&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0017">
<span class="label">17.</span><cite>
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed). 2022;75(6):523. doi: 10.1016/j.rec.2022.05.005

</cite> [<a href="https://doi.org/10.1016/j.rec.2022.05.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35636830/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Rev%20Esp%20Cardiol%20(Engl%20Ed)&amp;title=2021%20ESC%20guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure:%20developed%20by%20the%20task%20force%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure%20of%20the%20European%20Society%20of%20Cardiology%20(ESC)%20with%20the%20special%20contribution%20of%20the%20heart%20failure%20association%20(HFA)%20of%20the%20ESC&amp;author=TA%20McDonagh&amp;author=M%20Metra&amp;author=M%20Adamo&amp;volume=75&amp;issue=6&amp;publication_year=2022&amp;pages=523&amp;pmid=35636830&amp;doi=10.1016/j.rec.2022.05.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0018">
<span class="label">18.</span><cite>
McDonagh TA, Metra M, Adamo M, et al. Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627‐3639. doi: 10.1093/eurheartj/ehad195

</cite> [<a href="https://doi.org/10.1093/eurheartj/ehad195" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37622666/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Focused%20update%20of%20the%202021%20ESC%20guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure&amp;author=TA%20McDonagh&amp;author=M%20Metra&amp;author=M%20Adamo&amp;volume=44&amp;issue=37&amp;publication_year=2023&amp;pages=3627-3639&amp;pmid=37622666&amp;doi=10.1093/eurheartj/ehad195&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0019">
<span class="label">19.</span><cite>
Tsioufis C, Georgiopoulos G, Oikonomou D, et al. Hypertension and heart failure with preserved ejection fraction: connecting the dots. Curr Vasc Pharmacol. 2017;16(1):15‐22. doi: 10.2174/1570161115666170414120532

</cite> [<a href="https://doi.org/10.2174/1570161115666170414120532" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28413968/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Vasc%20Pharmacol&amp;title=Hypertension%20and%20heart%20failure%20with%20preserved%20ejection%20fraction:%20connecting%20the%20dots&amp;author=C%20Tsioufis&amp;author=G%20Georgiopoulos&amp;author=D%20Oikonomou&amp;volume=16&amp;issue=1&amp;publication_year=2017&amp;pages=15-22&amp;pmid=28413968&amp;doi=10.2174/1570161115666170414120532&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0020">
<span class="label">20.</span><cite>
Figtree GA, Radholm K, Barrett TD, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation. 2019;139(22):2591‐2593. doi: 10.1161/CIRCULATIONAHA.119.040057

</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.119.040057" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30882240/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Effects%20of%20canagliflozin%20on%20heart%20failure%20outcomes%20associated%20with%20preserved%20and%20reduced%20ejection%20fraction%20in%20type%202%20diabetes%20mellitus&amp;author=GA%20Figtree&amp;author=K%20Radholm&amp;author=TD%20Barrett&amp;volume=139&amp;issue=22&amp;publication_year=2019&amp;pages=2591-2593&amp;pmid=30882240&amp;doi=10.1161/CIRCULATIONAHA.119.040057&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0021">
<span class="label">21.</span><cite>
von Bibra H, St John Sutton M. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia. 2010;53(6):1033‐1045. doi: 10.1007/s00125-010-1682-3

</cite> [<a href="https://doi.org/10.1007/s00125-010-1682-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2860556/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20349347/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Diastolic%20dysfunction%20in%20diabetes%20and%20the%20metabolic%20syndrome:%20promising%20potential%20for%20diagnosis%20and%20prognosis&amp;author=H%20von%20Bibra&amp;author=M%20St%20John%20Sutton&amp;volume=53&amp;issue=6&amp;publication_year=2010&amp;pages=1033-1045&amp;pmid=20349347&amp;doi=10.1007/s00125-010-1682-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0022">
<span class="label">22.</span><cite>
Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk‐Noordegraaf A, Vachiery JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942‐954. doi: 10.1093/eurheartj/ehv512

</cite> [<a href="https://doi.org/10.1093/eurheartj/ehv512" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4800173/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26508169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Left%20ventricular%20heart%20failure%20and%20pulmonary%20hypertension&amp;author=S%20Rosenkranz&amp;author=JS%20Gibbs&amp;author=R%20Wachter&amp;author=T%20De%20Marco&amp;author=A%20Vonk%E2%80%90Noordegraaf&amp;volume=37&amp;issue=12&amp;publication_year=2016&amp;pages=942-954&amp;pmid=26508169&amp;doi=10.1093/eurheartj/ehv512&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0023">
<span class="label">23.</span><cite>
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411‐415. doi: 10.1038/332411a0

</cite> [<a href="https://doi.org/10.1038/332411a0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2451132/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A%20novel%20potent%20vasoconstrictor%20peptide%20produced%20by%20vascular%20endothelial%20cells&amp;author=M%20Yanagisawa&amp;author=H%20Kurihara&amp;author=S%20Kimura&amp;volume=332&amp;issue=6163&amp;publication_year=1988&amp;pages=411-415&amp;pmid=2451132&amp;doi=10.1038/332411a0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0024">
<span class="label">24.</span><cite>
Zolk O, Quattek J, Sitzler G, et al. Expression of endothelin‐1, endothelin‐converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999;99(16):2118‐2123. doi: 10.1161/01.cir.99.16.2118

</cite> [<a href="https://doi.org/10.1161/01.cir.99.16.2118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10217651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Expression%20of%20endothelin%E2%80%901,%20endothelin%E2%80%90converting%20enzyme,%20and%20endothelin%20receptors%20in%20chronic%20heart%20failure&amp;author=O%20Zolk&amp;author=J%20Quattek&amp;author=G%20Sitzler&amp;volume=99&amp;issue=16&amp;publication_year=1999&amp;pages=2118-2123&amp;pmid=10217651&amp;doi=10.1161/01.cir.99.16.2118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0025">
<span class="label">25.</span><cite>
Lindman BR, Davila‐Roman VG, Mann DL, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541‐549. doi: 10.1016/j.jacc.2014.05.030

</cite> [<a href="https://doi.org/10.1016/j.jacc.2014.05.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4133145/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25104521/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Cardiovascular%20phenotype%20in%20HFpEF%20patients%20with%20or%20without%20diabetes:%20a%20RELAX%20trial%20ancillary%20study&amp;author=BR%20Lindman&amp;author=VG%20Davila%E2%80%90Roman&amp;author=DL%20Mann&amp;volume=64&amp;issue=6&amp;publication_year=2014&amp;pages=541-549&amp;pmid=25104521&amp;doi=10.1016/j.jacc.2014.05.030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0026">
<span class="label">26.</span><cite>
Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27(12):2130‐2134. doi: 10.1093/cvr/27.12.2130

</cite> [<a href="https://doi.org/10.1093/cvr/27.12.2130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8313419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Res&amp;title=Effects%20of%20endothelins%20on%20collagen%20turnover%20in%20cardiac%20fibroblasts&amp;author=E%20Guarda&amp;author=LC%20Katwa&amp;author=PR%20Myers&amp;author=SC%20Tyagi&amp;author=KT%20Weber&amp;volume=27&amp;issue=12&amp;publication_year=1993&amp;pages=2130-2134&amp;pmid=8313419&amp;doi=10.1093/cvr/27.12.2130&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0027">
<span class="label">27.</span><cite>
Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115(7):888‐895. doi: 10.1161/CIRCULATIONAHA.106.638569

</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.106.638569" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17283265/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Diastolic%20heart%20failure:%20evidence%20of%20increased%20myocardial%20collagen%20turnover%20linked%20to%20diastolic%20dysfunction&amp;author=R%20Martos&amp;author=J%20Baugh&amp;author=M%20Ledwidge&amp;volume=115&amp;issue=7&amp;publication_year=2007&amp;pages=888-895&amp;pmid=17283265&amp;doi=10.1161/CIRCULATIONAHA.106.638569&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0028">
<span class="label">28.</span><cite>
Iglarz M, Landskroner K, Bauer Y, et al. Comparison of Macitentan and Bosentan on right ventricular remodeling in a rat model of non‐vasoreactive pulmonary hypertension. J Cardiovasc Pharmacol. 2015;66(5):457‐467. doi: 10.1097/FJC.0000000000000296

</cite> [<a href="https://doi.org/10.1097/FJC.0000000000000296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4632117/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26230396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Pharmacol&amp;title=Comparison%20of%20Macitentan%20and%20Bosentan%20on%20right%20ventricular%20remodeling%20in%20a%20rat%20model%20of%20non%E2%80%90vasoreactive%20pulmonary%20hypertension&amp;author=M%20Iglarz&amp;author=K%20Landskroner&amp;author=Y%20Bauer&amp;volume=66&amp;issue=5&amp;publication_year=2015&amp;pages=457-467&amp;pmid=26230396&amp;doi=10.1097/FJC.0000000000000296&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0029">
<span class="label">29.</span><cite>
Choudhary G, Troncales F, Martin D, Harrington EO, Klinger JR. Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. J Heart Lung Transplant. 2011;30(7):827‐833. doi: 10.1016/j.healun.2011.03.010

</cite> [<a href="https://doi.org/10.1016/j.healun.2011.03.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3536478/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21550822/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Heart%20Lung%20Transplant&amp;title=Bosentan%20attenuates%20right%20ventricular%20hypertrophy%20and%20fibrosis%20in%20normobaric%20hypoxia%20model%20of%20pulmonary%20hypertension&amp;author=G%20Choudhary&amp;author=F%20Troncales&amp;author=D%20Martin&amp;author=EO%20Harrington&amp;author=JR%20Klinger&amp;volume=30&amp;issue=7&amp;publication_year=2011&amp;pages=827-833&amp;pmid=21550822&amp;doi=10.1016/j.healun.2011.03.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0030">
<span class="label">30.</span><cite>
Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline‐induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J. 2010;36(4):800‐807. doi: 10.1183/09031936.00130209

</cite> [<a href="https://doi.org/10.1183/09031936.00130209" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20351034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Respir%20J&amp;title=Fasudil%20reduces%20monocrotaline%E2%80%90induced%20pulmonary%20arterial%20hypertension:%20comparison%20with%20bosentan%20and%20sildenafil&amp;author=KT%20Mouchaers&amp;author=I%20Schalij&amp;author=MA%20de%20Boer&amp;volume=36&amp;issue=4&amp;publication_year=2010&amp;pages=800-807&amp;pmid=20351034&amp;doi=10.1183/09031936.00130209&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0031">
<span class="label">31.</span><cite>
Chin KM, Kingman M, de Lemos JA, et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan‐treated patients with pulmonary arterial hypertension. Am J Cardiol. 2008;101(11):1669‐1672. doi: 10.1016/j.amjcard.2008.01.055

</cite> [<a href="https://doi.org/10.1016/j.amjcard.2008.01.055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18489949/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&amp;title=Changes%20in%20right%20ventricular%20structure%20and%20function%20assessed%20using%20cardiac%20magnetic%20resonance%20imaging%20in%20bosentan%E2%80%90treated%20patients%20with%20pulmonary%20arterial%20hypertension&amp;author=KM%20Chin&amp;author=M%20Kingman&amp;author=JA%20de%20Lemos&amp;volume=101&amp;issue=11&amp;publication_year=2008&amp;pages=1669-1672&amp;pmid=18489949&amp;doi=10.1016/j.amjcard.2008.01.055&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0032">
<span class="label">32.</span><cite>
Kim H, Bae Lee J, Park JH, et al. A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: results from a multicenter, prospective, cohort study. J Clin Ultrasound. 2017;45(1):28‐34. doi: 10.1002/jcu.22396

</cite> [<a href="https://doi.org/10.1002/jcu.22396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27619758/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Ultrasound&amp;title=A%20comparison%20of%20echocardiographic%20variables%20of%20right%20ventricular%20function%20with%20exercise%20capacity%20after%20bosentan%20treatment%20in%20patients%20with%20pulmonary%20arterial%20hypertension:%20results%20from%20a%20multicenter,%20prospective,%20cohort%20study&amp;author=H%20Kim&amp;author=J%20Bae%20Lee&amp;author=JH%20Park&amp;volume=45&amp;issue=1&amp;publication_year=2017&amp;pages=28-34&amp;pmid=27619758&amp;doi=10.1002/jcu.22396&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0033">
<span class="label">33.</span><cite>
Pulido T, Rubin LJ, Simonneau G. Macitentan and pulmonary arterial hypertension. N Engl J Med. 2014;370(1):82‐83. doi: 10.1056/NEJMc1313112
</cite> [<a href="https://doi.org/10.1056/NEJMc1313112" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24382071/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Macitentan%20and%20pulmonary%20arterial%20hypertension&amp;author=T%20Pulido&amp;author=LJ%20Rubin&amp;author=G%20Simonneau&amp;volume=370&amp;issue=1&amp;publication_year=2014&amp;pages=82-83&amp;pmid=24382071&amp;doi=10.1056/NEJMc1313112&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0034">
<span class="label">34.</span><cite>
Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Sci. 2020;4(1):e100115. doi: 10.1136/bmjos-2020-100115
</cite> [<a href="https://doi.org/10.1136/bmjos-2020-100115" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7610906/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34095516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20Open%20Sci&amp;title=The%20ARRIVE%20guidelines%202.0:%20updated%20guidelines%20for%20reporting%20animal%20research&amp;author=N%20Percie%20du%20Sert&amp;author=V%20Hurst&amp;author=A%20Ahluwalia&amp;volume=4&amp;issue=1&amp;publication_year=2020&amp;pages=e100115&amp;pmid=34095516&amp;doi=10.1136/bmjos-2020-100115&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0035">
<span class="label">35.</span><cite>
Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M. Vascular effects of endothelin receptor antagonists depends on their selectivity for ETA versus ETB receptors and on the functionality of endothelial ETB receptors. J Cardiovasc Pharmacol. 2015;66(4):332‐337. doi: 10.1097/FJC.0000000000000283

</cite> [<a href="https://doi.org/10.1097/FJC.0000000000000283" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4598072/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25992919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Pharmacol&amp;title=Vascular%20effects%20of%20endothelin%20receptor%20antagonists%20depends%20on%20their%20selectivity%20for%20ETA%20versus%20ETB%20receptors%20and%20on%20the%20functionality%20of%20endothelial%20ETB%20receptors&amp;author=M%20Iglarz&amp;author=P%20Steiner&amp;author=D%20Wanner&amp;author=M%20Rey&amp;author=P%20Hess&amp;volume=66&amp;issue=4&amp;publication_year=2015&amp;pages=332-337&amp;pmid=25992919&amp;doi=10.1097/FJC.0000000000000283&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0036">
<span class="label">36.</span><cite>
Brockway BP, Mills PA, Azar SH. A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radio‐telemetry. Clin Exp Hypertens A. 1991;13(5):885‐895. doi: 10.3109/10641969109042094

</cite> [<a href="https://doi.org/10.3109/10641969109042094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1773522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Exp%20Hypertens%20A&amp;title=A%20new%20method%20for%20continuous%20chronic%20measurement%20and%20recording%20of%20blood%20pressure,%20heart%20rate%20and%20activity%20in%20the%20rat%20via%20radio%E2%80%90telemetry&amp;author=BP%20Brockway&amp;author=PA%20Mills&amp;author=SH%20Azar&amp;volume=13&amp;issue=5&amp;publication_year=1991&amp;pages=885-895&amp;pmid=1773522&amp;doi=10.3109/10641969109042094&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0037">
<span class="label">37.</span><cite>
Mulder P, Boujedaini H, Richard V, et al. Selective endothelin‐a versus combined endothelin‐a/endothelin‐B receptor blockade in rat chronic heart failure. Circulation. 2000;102(5):491‐493. doi: 10.1161/01.cir.102.5.491

</cite> [<a href="https://doi.org/10.1161/01.cir.102.5.491" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10920058/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Selective%20endothelin%E2%80%90a%20versus%20combined%20endothelin%E2%80%90a/endothelin%E2%80%90B%20receptor%20blockade%20in%20rat%20chronic%20heart%20failure&amp;author=P%20Mulder&amp;author=H%20Boujedaini&amp;author=V%20Richard&amp;volume=102&amp;issue=5&amp;publication_year=2000&amp;pages=491-493&amp;pmid=10920058&amp;doi=10.1161/01.cir.102.5.491&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0038">
<span class="label">38.</span><cite>
Nahrendorf M, Hu K, Fraccarollo D, et al. Time course of right ventricular remodeling in rats with experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284(1):H241‐H248. doi: 10.1152/ajpheart.00537.2002

</cite> [<a href="https://doi.org/10.1152/ajpheart.00537.2002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12388245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Heart%20Circ%20Physiol&amp;title=Time%20course%20of%20right%20ventricular%20remodeling%20in%20rats%20with%20experimental%20myocardial%20infarction&amp;author=M%20Nahrendorf&amp;author=K%20Hu&amp;author=D%20Fraccarollo&amp;volume=284&amp;issue=1&amp;publication_year=2003&amp;pages=H241-H248&amp;pmid=12388245&amp;doi=10.1152/ajpheart.00537.2002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0039">
<span class="label">39.</span><cite>
Kober F, Iltis I, Cozzone PJ, Bernard M. Myocardial blood flow mapping in mice using high‐resolution spin labeling magnetic resonance imaging: influence of ketamine/xylazine and isoflurane anesthesia. Magn Reson Med. 2005;53(3):601‐606. doi: 10.1002/mrm.20373

</cite> [<a href="https://doi.org/10.1002/mrm.20373" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15723407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Magn%20Reson%20Med&amp;title=Myocardial%20blood%20flow%20mapping%20in%20mice%20using%20high%E2%80%90resolution%20spin%20labeling%20magnetic%20resonance%20imaging:%20influence%20of%20ketamine/xylazine%20and%20isoflurane%20anesthesia&amp;author=F%20Kober&amp;author=I%20Iltis&amp;author=PJ%20Cozzone&amp;author=M%20Bernard&amp;volume=53&amp;issue=3&amp;publication_year=2005&amp;pages=601-606&amp;pmid=15723407&amp;doi=10.1002/mrm.20373&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0040">
<span class="label">40.</span><cite>
Fang Y, Nicol L, Harouki N, et al. Improvement of left ventricular diastolic function induced by beta‐blockade A comparison between nebivolol and metoprolol. J Mol Cell Cardiol. 2011;51(2):168‐176. doi: 10.1016/j.yjmcc.2011.05.012

</cite> [<a href="https://doi.org/10.1016/j.yjmcc.2011.05.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21640121/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Cell%20Cardiol&amp;title=Improvement%20of%20left%20ventricular%20diastolic%20function%20induced%20by%20beta%E2%80%90blockade%20A%20comparison%20between%20nebivolol%20and%20metoprolol&amp;author=Y%20Fang&amp;author=L%20Nicol&amp;author=N%20Harouki&amp;volume=51&amp;issue=2&amp;publication_year=2011&amp;pages=168-176&amp;pmid=21640121&amp;doi=10.1016/j.yjmcc.2011.05.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0041">
<span class="label">41.</span><cite>
Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008;29:2171‐2179. doi: 10.1093/eurheartj/ehn277

</cite> [<a href="https://doi.org/10.1093/eurheartj/ehn277" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18586661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Aldosterone%20synthase%20inhibition%20improves%20cardiovascular%20function%20and%20structure%20in%20rats%20with%20heart%20failure:%20a%20comparison%20with%20spironolactone&amp;author=P%20Mulder&amp;author=V%20Mellin&amp;author=J%20Favre&amp;volume=29&amp;publication_year=2008&amp;pages=2171-2179&amp;pmid=18586661&amp;doi=10.1093/eurheartj/ehn277&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0042">
<span class="label">42.</span><cite>
Barbay V, Houssari M, Mekki M, et al. Role of M2‐like macrophage recruitment during angiogenic growth factor therapy. Angiogenesis. 2015;18(2):191‐200. doi: 10.1007/s10456-014-9456-z

</cite> [<a href="https://doi.org/10.1007/s10456-014-9456-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25537851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Angiogenesis&amp;title=Role%20of%20M2%E2%80%90like%20macrophage%20recruitment%20during%20angiogenic%20growth%20factor%20therapy&amp;author=V%20Barbay&amp;author=M%20Houssari&amp;author=M%20Mekki&amp;volume=18&amp;issue=2&amp;publication_year=2015&amp;pages=191-200&amp;pmid=25537851&amp;doi=10.1007/s10456-014-9456-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0043">
<span class="label">43.</span><cite>
Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long‐term allopurinol treatment initiated in established chronic heart failure. EurHeart J. 2005;26(15):1544‐1550. doi: 10.1093/eurheartj/ehi305
</cite> [<a href="https://doi.org/10.1093/eurheartj/ehi305" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15872033/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EurHeart%20J&amp;title=Transient%20reduction%20in%20myocardial%20free%20oxygen%20radical%20levels%20is%20involved%20in%20the%20improved%20cardiac%20function%20and%20structure%20after%20long%E2%80%90term%20allopurinol%20treatment%20initiated%20in%20established%20chronic%20heart%20failure&amp;author=V%20Mellin&amp;author=M%20Isabelle&amp;author=A%20Oudot&amp;volume=26&amp;issue=15&amp;publication_year=2005&amp;pages=1544-1550&amp;pmid=15872033&amp;doi=10.1093/eurheartj/ehi305&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0044">
<span class="label">44.</span><cite>
Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation. 1994;89(3):1254‐1261. doi: 10.1161/01.cir.89.3.1254

</cite> [<a href="https://doi.org/10.1161/01.cir.89.3.1254" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8124814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Ischemic%20preconditioning%20protects%20against%20coronary%20endothelial%20dysfunction%20induced%20by%20ischemia%20and%20reperfusion&amp;author=V%20Richard&amp;author=N%20Kaeffer&amp;author=C%20Tron&amp;author=C%20Thuillez&amp;volume=89&amp;issue=3&amp;publication_year=1994&amp;pages=1254-1261&amp;pmid=8124814&amp;doi=10.1161/01.cir.89.3.1254&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0045">
<span class="label">45.</span><cite>
Merabet N, Fang Y, Nicol L, et al. Selective heart rate reduction improves metabolic syndrome‐related left ventricular diastolic dysfunction. J Cardiovasc Pharmacol. 2015;66(4):399‐408. doi: 10.1097/FJC.0000000000000294

</cite> [<a href="https://doi.org/10.1097/FJC.0000000000000294" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26222991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Pharmacol&amp;title=Selective%20heart%20rate%20reduction%20improves%20metabolic%20syndrome%E2%80%90related%20left%20ventricular%20diastolic%20dysfunction&amp;author=N%20Merabet&amp;author=Y%20Fang&amp;author=L%20Nicol&amp;volume=66&amp;issue=4&amp;publication_year=2015&amp;pages=399-408&amp;pmid=26222991&amp;doi=10.1097/FJC.0000000000000294&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0046">
<span class="label">46.</span><cite>
Nishimatsu H, Suzuki E, Satonaka H, et al. Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2005;288(4):H1770‐H1776. doi: 10.1152/ajpheart.00751.2004

</cite> [<a href="https://doi.org/10.1152/ajpheart.00751.2004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15550522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Heart%20Circ%20Physiol&amp;title=Endothelial%20dysfunction%20and%20hypercontractility%20of%20vascular%20myocytes%20are%20ameliorated%20by%20fluvastatin%20in%20obese%20Zucker%20rats&amp;author=H%20Nishimatsu&amp;author=E%20Suzuki&amp;author=H%20Satonaka&amp;volume=288&amp;issue=4&amp;publication_year=2005&amp;pages=H1770-H1776&amp;pmid=15550522&amp;doi=10.1152/ajpheart.00751.2004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0047">
<span class="label">47.</span><cite>
Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol. 2006;291(4):H1780‐H1787. doi: 10.1152/ajpheart.01297.2005

</cite> [<a href="https://doi.org/10.1152/ajpheart.01297.2005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16714356/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Heart%20Circ%20Physiol&amp;title=Progression%20of%20coronary%20and%20mesenteric%20vascular%20dysfunction%20in%20Zucker%20obese%20and%20Zucker%20diabetic%20fatty%20rats&amp;author=CL%20Oltman&amp;author=LL%20Richou&amp;author=EP%20Davidson&amp;author=LJ%20Coppey&amp;author=DD%20Lund&amp;volume=291&amp;issue=4&amp;publication_year=2006&amp;pages=H1780-H1787&amp;pmid=16714356&amp;doi=10.1152/ajpheart.01297.2005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0048">
<span class="label">48.</span><cite>
Aleixandre de Artinano A, Miguel CM. Experimental rat models to study the metabolic syndrome. Br J Nutr. 2009;102(9):1246‐1253. doi: 10.1017/S0007114509990729

</cite> [<a href="https://doi.org/10.1017/S0007114509990729" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19631025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Nutr&amp;title=Experimental%20rat%20models%20to%20study%20the%20metabolic%20syndrome&amp;author=A%20Aleixandre%20de%20Artinano&amp;author=CM%20Miguel&amp;volume=102&amp;issue=9&amp;publication_year=2009&amp;pages=1246-1253&amp;pmid=19631025&amp;doi=10.1017/S0007114509990729&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0049">
<span class="label">49.</span><cite>
Debin R, Lauzier B, Sicard P, et al. Are Zucker obese rats a useful model for cardiovascular complications in metabolic syndrome? Physical, biochemical and oxidative stress considerations. Fundam Clin Pharmacol. 2009;23(1):59‐67. doi: 10.1111/j.1472-8206.2008.00659.x

</cite> [<a href="https://doi.org/10.1111/j.1472-8206.2008.00659.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19267771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Fundam%20Clin%20Pharmacol&amp;title=Are%20Zucker%20obese%20rats%20a%20useful%20model%20for%20cardiovascular%20complications%20in%20metabolic%20syndrome?%20Physical,%20biochemical%20and%20oxidative%20stress%20considerations&amp;author=R%20Debin&amp;author=B%20Lauzier&amp;author=P%20Sicard&amp;volume=23&amp;issue=1&amp;publication_year=2009&amp;pages=59-67&amp;pmid=19267771&amp;doi=10.1111/j.1472-8206.2008.00659.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0050">
<span class="label">50.</span><cite>
Kwitek AE. Rat models of metabolic syndrome. Methods Mol Biol. 2019;2018:269‐285. doi: 10.1007/978-1-4939-9581-3_13

</cite> [<a href="https://doi.org/10.1007/978-1-4939-9581-3_13" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7315404/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31228162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Methods%20Mol%20Biol&amp;title=Rat%20models%20of%20metabolic%20syndrome&amp;author=AE%20Kwitek&amp;volume=2018&amp;publication_year=2019&amp;pages=269-285&amp;pmid=31228162&amp;doi=10.1007/978-1-4939-9581-3_13&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0051">
<span class="label">51.</span><cite>
Rawat DK, Alzoubi A, Gupte R, et al. Increased reactive oxygen species, metabolic maladaptation, and autophagy contribute to pulmonary arterial hypertension‐induced ventricular hypertrophy and diastolic heart failure. Hypertension. 2014;64(6):1266‐1274. doi: 10.1161/HYPERTENSIONAHA.114.03261

</cite> [<a href="https://doi.org/10.1161/HYPERTENSIONAHA.114.03261" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25267798/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hypertension&amp;title=Increased%20reactive%20oxygen%20species,%20metabolic%20maladaptation,%20and%20autophagy%20contribute%20to%20pulmonary%20arterial%20hypertension%E2%80%90induced%20ventricular%20hypertrophy%20and%20diastolic%20heart%20failure&amp;author=DK%20Rawat&amp;author=A%20Alzoubi&amp;author=R%20Gupte&amp;volume=64&amp;issue=6&amp;publication_year=2014&amp;pages=1266-1274&amp;pmid=25267798&amp;doi=10.1161/HYPERTENSIONAHA.114.03261&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0052">
<span class="label">52.</span><cite>
Thenappan T, Prins KW, Cogswell R, Shah SJ. Pulmonary hypertension secondary to heart failure with preserved ejection fraction. Can J Cardiol. 2015;31(4):430‐439. doi: 10.1016/j.cjca.2014.12.028

</cite> [<a href="https://doi.org/10.1016/j.cjca.2014.12.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25840094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Cardiol&amp;title=Pulmonary%20hypertension%20secondary%20to%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;author=T%20Thenappan&amp;author=KW%20Prins&amp;author=R%20Cogswell&amp;author=SJ%20Shah&amp;volume=31&amp;issue=4&amp;publication_year=2015&amp;pages=430-439&amp;pmid=25840094&amp;doi=10.1016/j.cjca.2014.12.028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0053">
<span class="label">53.</span><cite>
Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575‐584. doi: 10.1016/j.cjca.2017.12.005

</cite> [<a href="https://doi.org/10.1016/j.cjca.2017.12.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5953551/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29459239/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Cardiol&amp;title=Diabetes,%20hypertension,%20and%20cardiovascular%20disease:%20clinical%20insights%20and%20vascular%20mechanisms&amp;author=JR%20Petrie&amp;author=TJ%20Guzik&amp;author=RM%20Touyz&amp;volume=34&amp;issue=5&amp;publication_year=2018&amp;pages=575-584&amp;pmid=29459239&amp;doi=10.1016/j.cjca.2017.12.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0054">
<span class="label">54.</span><cite>
Loffler BM, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non‐peptide antagonist Ro 46‐2005 on endothelin levels in rat plasma. FEBS Lett. 1993;333(1–2):108‐110. doi: 10.1016/0014-5793(93)80384-7

</cite> [<a href="https://doi.org/10.1016/0014-5793(93)80384-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8224145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Lett&amp;title=Effect%20of%20different%20endothelin%20receptor%20antagonists%20and%20of%20the%20novel%20non%E2%80%90peptide%20antagonist%20Ro%2046%E2%80%902005%20on%20endothelin%20levels%20in%20rat%20plasma&amp;author=BM%20Loffler&amp;author=V%20Breu&amp;author=M%20Clozel&amp;volume=333&amp;issue=1%E2%80%932&amp;publication_year=1993&amp;pages=108-110&amp;pmid=8224145&amp;doi=10.1016/0014-5793(93)80384-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0055">
<span class="label">55.</span><cite>
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809‐818. doi: 10.1056/NEJMoa1213917

</cite> [<a href="https://doi.org/10.1056/NEJMoa1213917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23984728/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Macitentan%20and%20morbidity%20and%20mortality%20in%20pulmonary%20arterial%20hypertension&amp;author=T%20Pulido&amp;author=I%20Adzerikho&amp;author=RN%20Channick&amp;volume=369&amp;issue=9&amp;publication_year=2013&amp;pages=809-818&amp;pmid=23984728&amp;doi=10.1056/NEJMoa1213917&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0056">
<span class="label">56.</span><cite>
Galie N, Jansa P, Pulido T, et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT‐proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017;38(15):1147‐1155. doi: 10.1093/eurheartj/ehx025

</cite> [<a href="https://doi.org/10.1093/eurheartj/ehx025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5400052/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28329315/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=SERAPHIN%20haemodynamic%20substudy:%20the%20effect%20of%20the%20dual%20endothelin%20receptor%20antagonist%20macitentan%20on%20haemodynamic%20parameters%20and%20NT%E2%80%90proBNP%20levels%20and%20their%20association%20with%20disease%20progression%20in%20patients%20with%20pulmonary%20arterial%20hypertension&amp;author=N%20Galie&amp;author=P%20Jansa&amp;author=T%20Pulido&amp;volume=38&amp;issue=15&amp;publication_year=2017&amp;pages=1147-1155&amp;pmid=28329315&amp;doi=10.1093/eurheartj/ehx025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0057">
<span class="label">57.</span><cite>
Nielsen EA, Sun M, Honjo O, Hjortdal VE, Redington AN, Friedberg MK. Dual endothelin receptor blockade abrogates right ventricular remodeling and biventricular fibrosis in isolated elevated right ventricular afterload. PLoS ONE. 2016;11(1):e0146767. doi: 10.1371/journal.pone.0146767

</cite> [<a href="https://doi.org/10.1371/journal.pone.0146767" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4713098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26765263/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Dual%20endothelin%20receptor%20blockade%20abrogates%20right%20ventricular%20remodeling%20and%20biventricular%20fibrosis%20in%20isolated%20elevated%20right%20ventricular%20afterload&amp;author=EA%20Nielsen&amp;author=M%20Sun&amp;author=O%20Honjo&amp;author=VE%20Hjortdal&amp;author=AN%20Redington&amp;volume=11&amp;issue=1&amp;publication_year=2016&amp;pages=e0146767&amp;pmid=26765263&amp;doi=10.1371/journal.pone.0146767&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0058">
<span class="label">58.</span><cite>
Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11(1):12‐20. doi: 10.1016/j.cardfail.2004.05.006

</cite> [<a href="https://doi.org/10.1016/j.cardfail.2004.05.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15704058/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Card%20Fail&amp;title=Clinical%20effects%20of%20endothelin%20receptor%20antagonism%20with%20bosentan%20in%20patients%20with%20severe%20chronic%20heart%20failure:%20results%20of%20a%20pilot%20study&amp;author=M%20Packer&amp;author=J%20McMurray&amp;author=BM%20Massie&amp;volume=11&amp;issue=1&amp;publication_year=2005&amp;pages=12-20&amp;pmid=15704058&amp;doi=10.1016/j.cardfail.2004.05.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0059">
<span class="label">59.</span><cite>
Packer M, McMurray JJV, Krum H, et al. Long‐term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail. 2017;5(5):317‐326. doi: 10.1016/j.jchf.2017.02.021

</cite> [<a href="https://doi.org/10.1016/j.jchf.2017.02.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28449795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Heart%20Fail&amp;title=Long%E2%80%90term%20effect%20of%20endothelin%20receptor%20antagonism%20with%20bosentan%20on%20the%20morbidity%20and%20mortality%20of%20patients%20with%20severe%20chronic%20heart%20failure:%20primary%20results%20of%20the%20ENABLE%20trials&amp;author=M%20Packer&amp;author=JJV%20McMurray&amp;author=H%20Krum&amp;volume=5&amp;issue=5&amp;publication_year=2017&amp;pages=317-326&amp;pmid=28449795&amp;doi=10.1016/j.jchf.2017.02.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0060">
<span class="label">60.</span><cite>
Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long‐ term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96(6):1976‐1982. doi: 10.1161/01.cir.96.6.1976

</cite> [<a href="https://doi.org/10.1161/01.cir.96.6.1976" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9323089/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Role%20of%20endogenous%20endothelin%20in%20chronic%20heart%20failure:%20effect%20of%20long%E2%80%90%20term%20treatment%20with%20an%20endothelin%20antagonist%20on%20survival,%20hemodynamics,%20and%20cardiac%20remodeling&amp;author=P%20Mulder&amp;author=V%20Richard&amp;author=G%20Derumeaux&amp;volume=96&amp;issue=6&amp;publication_year=1997&amp;pages=1976-1982&amp;pmid=9323089&amp;doi=10.1161/01.cir.96.6.1976&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0061">
<span class="label">61.</span><cite>
Lachaux MSM, Hamzaoui M, Bailly B, et al. Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome. Endocrinol Diab Metab. 2020;e00128. doi: 10.1002/edm2.128
</cite> [<a href="https://doi.org/10.1002/edm2.128" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7375119/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32704553/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocrinol%20Diab%20Metab&amp;title=Short%E2%80%90and%20long%E2%80%90term%20administration%20of%20imeglimin%20counters%20cardiorenal%20dysfunction%20in%20a%20rat%20model%20of%20metabolic%20syndrome&amp;author=MSM%20Lachaux&amp;author=M%20Hamzaoui&amp;author=B%20Bailly&amp;publication_year=2020&amp;pages=e00128&amp;pmid=32704553&amp;doi=10.1002/edm2.128&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0062">
<span class="label">62.</span><cite>
Wedgwood S, Dettman RW, Black SM. ET‐1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol. 2001;281(5):L1058‐L1067. doi: 10.1152/ajplung.2001.281.5.L1058

</cite> [<a href="https://doi.org/10.1152/ajplung.2001.281.5.L1058" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11597896/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Lung%20Cell%20Mol%20Physiol&amp;title=ET%E2%80%901%20stimulates%20pulmonary%20arterial%20smooth%20muscle%20cell%20proliferation%20via%20induction%20of%20reactive%20oxygen%20species&amp;author=S%20Wedgwood&amp;author=RW%20Dettman&amp;author=SM%20Black&amp;volume=281&amp;issue=5&amp;publication_year=2001&amp;pages=L1058-L1067&amp;pmid=11597896&amp;doi=10.1152/ajplung.2001.281.5.L1058&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0063">
<span class="label">63.</span><cite>
Kuster GM, Lancel S, Zhang J, et al. Free Radic Biol Med. 2010;48(9):1182‐1187. doi: 10.1016/j.freeradbiomed.2010.01.038

</cite> [<a href="https://doi.org/10.1016/j.freeradbiomed.2010.01.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2847633/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20132882/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Free%20Radic%20Biol%20Med&amp;author=GM%20Kuster&amp;author=S%20Lancel&amp;author=J%20Zhang&amp;volume=48&amp;issue=9&amp;publication_year=2010&amp;pages=1182-1187&amp;pmid=20132882&amp;doi=10.1016/j.freeradbiomed.2010.01.038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0064">
<span class="label">64.</span><cite>
Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280(1):C53‐C60. doi: 10.1152/ajpcell.2001.280.1.C53

</cite> [<a href="https://doi.org/10.1152/ajpcell.2001.280.1.C53" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11121376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Cell%20Physiol&amp;title=Oxidative%20stress%20regulates%20collagen%20synthesis%20and%20matrix%20metalloproteinase%20activity%20in%20cardiac%20fibroblasts&amp;author=DA%20Siwik&amp;author=PJ%20Pagano&amp;author=WS%20Colucci&amp;volume=280&amp;issue=1&amp;publication_year=2001&amp;pages=C53-C60&amp;pmid=11121376&amp;doi=10.1152/ajpcell.2001.280.1.C53&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0065">
<span class="label">65.</span><cite>
Mulder P, Barbier S, Chagraoui A, et al. Long‐term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109(13):1674‐1679. doi: 10.1161/01.CIR.0000118464.48959.1C

</cite> [<a href="https://doi.org/10.1161/01.CIR.0000118464.48959.1C" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14981003/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Long%E2%80%90term%20heart%20rate%20reduction%20induced%20by%20the%20selective%20I(f)%20current%20inhibitor%20ivabradine%20improves%20left%20ventricular%20function%20and%20intrinsic%20myocardial%20structure%20in%20congestive%20heart%20failure&amp;author=P%20Mulder&amp;author=S%20Barbier&amp;author=A%20Chagraoui&amp;volume=109&amp;issue=13&amp;publication_year=2004&amp;pages=1674-1679&amp;pmid=14981003&amp;doi=10.1161/01.CIR.0000118464.48959.1C&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0066">
<span class="label">66.</span><cite>
Harouki N, Nicol L, Remy‐Jouet I, et al. The IL‐1beta antibody Gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure. JACC Basic to Transl Sci. 2017;2(4):418‐430. doi: 10.1016/j.jacbts.2017.06.005
</cite> [<a href="https://doi.org/10.1016/j.jacbts.2017.06.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6034492/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30062160/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Basic%20to%20Transl%20Sci&amp;title=The%20IL%E2%80%901beta%20antibody%20Gevokizumab%20limits%20cardiac%20remodeling%20and%20coronary%20dysfunction%20in%20rats%20with%20heart%20failure&amp;author=N%20Harouki&amp;author=L%20Nicol&amp;author=I%20Remy%E2%80%90Jouet&amp;volume=2&amp;issue=4&amp;publication_year=2017&amp;pages=418-430&amp;pmid=30062160&amp;doi=10.1016/j.jacbts.2017.06.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0067">
<span class="label">67.</span><cite>
Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation. 2008;118(8):818‐827. doi: 10.1161/CIRCULATIONAHA.107.717702

</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.107.717702" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18678774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Improvement%20in%20left%20ventricular%20remodeling%20by%20the%20endothelial%20nitric%20oxide%20synthase%20enhancer%20AVE9488%20after%20experimental%20myocardial%20infarction&amp;author=D%20Fraccarollo&amp;author=JD%20Widder&amp;author=P%20Galuppo&amp;volume=118&amp;issue=8&amp;publication_year=2008&amp;pages=818-827&amp;pmid=18678774&amp;doi=10.1161/CIRCULATIONAHA.107.717702&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0068">
<span class="label">68.</span><cite>
Correale M, Mazzeo P, Mallardi A, et al. Switch to SGLT2 inhibitors and improved endothelial function in diabetic patients with chronic heart failure. Cardiovasc Drugs Ther. 2022;36(6):1157‐1164. doi: 10.1007/s10557-021-07254-3

</cite> [<a href="https://doi.org/10.1007/s10557-021-07254-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9652233/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34519913/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Drugs%20Ther&amp;title=Switch%20to%20SGLT2%20inhibitors%20and%20improved%20endothelial%20function%20in%20diabetic%20patients%20with%20chronic%20heart%20failure&amp;author=M%20Correale&amp;author=P%20Mazzeo&amp;author=A%20Mallardi&amp;volume=36&amp;issue=6&amp;publication_year=2022&amp;pages=1157-1164&amp;pmid=34519913&amp;doi=10.1007/s10557-021-07254-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0069">
<span class="label">69.</span><cite>
Fonseca‐Correa JI, Correa‐Rotter R. Sodium‐glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne). 2021;8:777861. doi: 10.3389/fmed.2021.777861

</cite> [<a href="https://doi.org/10.3389/fmed.2021.777861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8720766/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34988095/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Med%20(Lausanne)&amp;title=Sodium%E2%80%90glucose%20cotransporter%202%20inhibitors%20mechanisms%20of%20action:%20a%20review&amp;author=JI%20Fonseca%E2%80%90Correa&amp;author=R%20Correa%E2%80%90Rotter&amp;volume=8&amp;publication_year=2021&amp;pages=777861&amp;pmid=34988095&amp;doi=10.3389/fmed.2021.777861&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0070">
<span class="label">70.</span><cite>
Esser N, Zraika S. Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Diabetologia. 2019;62(7):1113‐1122. doi: 10.1007/s00125-019-4889-y

</cite> [<a href="https://doi.org/10.1007/s00125-019-4889-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6579747/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31089754/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Neprilysin%20inhibition:%20a%20new%20therapeutic%20option%20for%20type%202%20diabetes?&amp;author=N%20Esser&amp;author=S%20Zraika&amp;volume=62&amp;issue=7&amp;publication_year=2019&amp;pages=1113-1122&amp;pmid=31089754&amp;doi=10.1007/s00125-019-4889-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0071">
<span class="label">71.</span><cite>
Lachaux M, Barrera‐Chimal J, Nicol L, et al. Short‐ and long‐term administration of the non‐steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome‐related cardio‐renal dysfunction. Diabetes Obes Metab. 2018;20(10):2399‐2407. doi: 10.1111/dom.13393

</cite> [<a href="https://doi.org/10.1111/dom.13393" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29862614/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Short%E2%80%90%20and%20long%E2%80%90term%20administration%20of%20the%20non%E2%80%90steroidal%20mineralocorticoid%20receptor%20antagonist%20finerenone%20opposes%20metabolic%20syndrome%E2%80%90related%20cardio%E2%80%90renal%20dysfunction&amp;author=M%20Lachaux&amp;author=J%20Barrera%E2%80%90Chimal&amp;author=L%20Nicol&amp;volume=20&amp;issue=10&amp;publication_year=2018&amp;pages=2399-2407&amp;pmid=29862614&amp;doi=10.1111/dom.13393&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0072">
<span class="label">72.</span><cite>
Browatzki M, Schmidt J, Kubler W, Kranzhofer R. Endothelin‐1 induces interleukin‐6 release via activation of the transcription factor NF‐kappaB in human vascular smooth muscle cells. Basic Res Cardiol. 2000;95(2):98‐105. doi: 10.1007/s003950050170

</cite> [<a href="https://doi.org/10.1007/s003950050170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10826501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Basic%20Res%20Cardiol&amp;title=Endothelin%E2%80%901%20induces%20interleukin%E2%80%906%20release%20via%20activation%20of%20the%20transcription%20factor%20NF%E2%80%90kappaB%20in%20human%20vascular%20smooth%20muscle%20cells&amp;author=M%20Browatzki&amp;author=J%20Schmidt&amp;author=W%20Kubler&amp;author=R%20Kranzhofer&amp;volume=95&amp;issue=2&amp;publication_year=2000&amp;pages=98-105&amp;pmid=10826501&amp;doi=10.1007/s003950050170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0073">
<span class="label">73.</span><cite>
Bukowska A, Nikonova Y, Wolke C, Lendeckel U, Kockskamper J, Goette A. Anti‐inflammatory effects of endothelin receptor blockade in left atrial tissue of spontaneously hypertensive rats. Int J Cardiol Heart Vasc. 2022;42:101088. doi: 10.1016/j.ijcha.2022.101088

</cite> [<a href="https://doi.org/10.1016/j.ijcha.2022.101088" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9307454/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35879971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cardiol%20Heart%20Vasc&amp;title=Anti%E2%80%90inflammatory%20effects%20of%20endothelin%20receptor%20blockade%20in%20left%20atrial%20tissue%20of%20spontaneously%20hypertensive%20rats&amp;author=A%20Bukowska&amp;author=Y%20Nikonova&amp;author=C%20Wolke&amp;author=U%20Lendeckel&amp;author=J%20Kockskamper&amp;volume=42&amp;publication_year=2022&amp;pages=101088&amp;pmid=35879971&amp;doi=10.1016/j.ijcha.2022.101088&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0074">
<span class="label">74.</span><cite>
Medina‐Leyte DJ, Zepeda‐Garcia O, Dominguez‐Perez M, Gonzalez‐Garrido A, Villarreal‐Molina T, Jacobo‐Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850. doi: 10.3390/ijms22083850

</cite> [<a href="https://doi.org/10.3390/ijms22083850" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8068178/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33917744/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Endothelial%20dysfunction,%20inflammation%20and%20coronary%20artery%20disease:%20potential%20biomarkers%20and%20promising%20therapeutical%20approaches&amp;author=DJ%20Medina%E2%80%90Leyte&amp;author=O%20Zepeda%E2%80%90Garcia&amp;author=M%20Dominguez%E2%80%90Perez&amp;author=A%20Gonzalez%E2%80%90Garrido&amp;author=T%20Villarreal%E2%80%90Molina&amp;volume=22&amp;issue=8&amp;publication_year=2021&amp;pages=3850&amp;pmid=33917744&amp;doi=10.3390/ijms22083850&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0075">
<span class="label">75.</span><cite>
Xu G, Gong Y, Lu F, et al. Endothelin receptor B enhances liver injury and pro‐inflammatory responses by increasing G‐protein‐coupled receptor kinase‐2 expression in primary biliary cholangitis. Sci Rep. 2022;12(1):19772. doi: 10.1038/s41598-022-21816-x

</cite> [<a href="https://doi.org/10.1038/s41598-022-21816-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9672122/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36396948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Endothelin%20receptor%20B%20enhances%20liver%20injury%20and%20pro%E2%80%90inflammatory%20responses%20by%20increasing%20G%E2%80%90protein%E2%80%90coupled%20receptor%20kinase%E2%80%902%20expression%20in%20primary%20biliary%20cholangitis&amp;author=G%20Xu&amp;author=Y%20Gong&amp;author=F%20Lu&amp;volume=12&amp;issue=1&amp;publication_year=2022&amp;pages=19772&amp;pmid=36396948&amp;doi=10.1038/s41598-022-21816-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0076">
<span class="label">76.</span><cite>
Czopek A, Moorhouse R, Guyonnet L, et al. A novel role for myeloid endothelin‐B receptors in hypertension. Eur Heart J. 2019;40(9):768‐784. doi: 10.1093/eurheartj/ehy881

</cite> [<a href="https://doi.org/10.1093/eurheartj/ehy881" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6396028/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30657897/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=A%20novel%20role%20for%20myeloid%20endothelin%E2%80%90B%20receptors%20in%20hypertension&amp;author=A%20Czopek&amp;author=R%20Moorhouse&amp;author=L%20Guyonnet&amp;volume=40&amp;issue=9&amp;publication_year=2019&amp;pages=768-784&amp;pmid=30657897&amp;doi=10.1093/eurheartj/ehy881&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0077">
<span class="label">77.</span><cite>
Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol. 2007;47(1):731‐759. doi: 10.1146/annurev.pharmtox.47.120505.105134

</cite> [<a href="https://doi.org/10.1146/annurev.pharmtox.47.120505.105134" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2825895/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17002597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Pharmacol%20Toxicol&amp;title=Contrasting%20actions%20of%20endothelin%20ET(A)%20and%20ET(B)%20receptors%20in%20cardiovascular%20disease&amp;author=MP%20Schneider&amp;author=EI%20Boesen&amp;author=DM%20Pollock&amp;volume=47&amp;issue=1&amp;publication_year=2007&amp;pages=731-759&amp;pmid=17002597&amp;doi=10.1146/annurev.pharmtox.47.120505.105134&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70006-bib-0078">
<span class="label">78.</span><cite>
Monaco TJ, Davila CD. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2016;10:1675‐1682. doi: 10.2147/DDDT.S88612
</cite> [<a href="https://doi.org/10.2147/DDDT.S88612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4876803/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27274200/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Des%20Devel%20Ther&amp;title=Safety,%20efficacy,%20and%20clinical%20utility%20of%20macitentan%20in%20the%20treatment%20of%20pulmonary%20arterial%20hypertension&amp;author=TJ%20Monaco&amp;author=CD%20Davila&amp;volume=10&amp;publication_year=2016&amp;pages=1675-1682&amp;pmid=27274200&amp;doi=10.2147/DDDT.S88612&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p">
<p>
<strong>Table S1.</strong> Blood pressure at 90 days numerical data.</p>
<p>
<strong>Table S2.</strong> Right and left ventricular coronary artery relaxation at 10<sup>–4.5</sup> M Acetylcholine numerical data.</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11981691/bin/FCP-39-0-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">FCP-39-0-s001.docx</a><sup> (18.3KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Further study data are available upon reasonable request to the corresponding author.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Fundamental &amp; Clinical Pharmacology are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1111/fcp.70006"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/FCP-39-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (3.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11981691/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11981691/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11981691%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11981691/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11981691/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11981691/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40203840/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11981691/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40203840/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11981691/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11981691/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="O19e9LhMCLalDOBGkgXC3vDP8LgLXxKv94WqXC31IxALc9oVYhkoUIrx7DKP8UmT">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
